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2Welcome to the 6th Northern Ireland Stroke Conference organised in 
partnership between the Northern Ireland Multidisciplinary Association for 
Stroke Teams (NIMAST) and the UK Stroke Forum (UKSF). 
We hope you enjoy the day and the variety of sessions planned for our 
multidisciplinary audience by the Conference Planning Committee. 
Thanks to our sponsors:
Gold:
Silver:  
Bronze:  
Lanyards sponsored by:  
Breathe. Eat. Smile. Talk.
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4Useful Information
Venue 
•  Conference sessions will take place on the ﬁrst ﬂoor in the Grand Ballroom
•   Exhibition and charity stands are located in the Grand Ballroom Pre-function Lounge and Poster 
Room
•  Research posters, including ongoing trials, are in the Grand Ballroom sub-section 2
WIFI 
Internet access is available free of charge throughout the venue.  
Enquiries
The Enquiries Desk is located outside the Grand Ballroom on the ﬁrst ﬂoor. 
First Aid
Delegates requiring ﬁrst aid are asked to report to venue or conference staff for assistance.
Refreshments
Tea, coffee and lunch are included for all delegates and will be served in the Exhibition areas and 
Poster Room. Delegates are welcome to use seating in session rooms during refreshment breaks 
(rooms will be cleared 30 minutes before the next session starts).
Speaker Presentation slides
Presentation slides, where permitted, will be available on www.ukstrokeforum.org after the event. 
CPD and Evaluation
Accreditation has been awarded from the Federation of the Royal Colleges of Physicians of the United 
Kingdom for 6 category 1 (external) CPD credits. 
CPD certiﬁcates will be issued upon completion of the on-line conference evaluation form. 
Your feedback is extremely valuable to ensure the event continues to improve and meet your needs 
each year and we welcome any feedback you have. 
The online evaluation form will be sent to you by email after the event. 
This service is kindly provided by   
Photography
Our team will be taking photographs throughout the conference and we may use some of the images 
taken for promotional purposes (including our website and social media). Please let us know if you 
have any concerns about this.
5Floorplan
Exhibition stands
Stand 1 – BMS/Pﬁzer Alliance
Stand 2 – MYoroface 
Stand 3 – Kainos Evolve / InTouch Health
Stand 4 – Bayer
Stand 5 – Medtronic
Stand 6 – Nestlé
Stand 7 – NI Clinical Research Network
Stand 8 – Daiichi Sankyo
Stand 9 – Connected Care Solutions
Stand 10 – Kora Healthcare
Stand 11 – Silverlink
Stand 12 – SSNAP/Royal College of Physicians
Stand 13 – Saebo 
Stand 14 – Allergan
Stand 16 – Stryker
Stand 17 – Capita
Stand 18 – Nihon Kohden UK Ltd
Stand 19 – Novacor
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ELIQUIS® (apixaban)  2.5 mg & 5 mg Film-coated Tablets Prescribing Information 
Consult summary of product characteristics (SmPC) prior to prescribing and for full 
list of adverse events. PRESENTATION: Film-coated tablets; 2.5mg and 5mg 
apixaban. INDICATION: Prevention of stroke and systemic embolism in adult 
patients with non-valvular atrial ﬁbrillation (NVAF) with one or more risk factors, 
such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, 
diabetes mellitus or symptomatic heart failure (NYHA Class ≥II). Treatment of deep 
vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent 
DVT and PE in adults (see Special warnings and precautions for information on 
haemodynamically unstable PE patients). Prevention of venous thromboembolic 
events (VTE) in adult patients who have undergone elective hip or knee 
replacement surgery (2.5 mg only). DOSAGE AND ADMINISTRATION: Oral. Taken 
with water, with or without food. Prevention of stroke and systemic embolism in 
patients with NVAF: The recommended dose is 5 mg taken twice a day. Patients 
who meet at least two of the following criteria: serum creatinine ≥1.5 mg/dL (133 
micromole/l), age ≥80 years, or body weight ≤60 kg should receive the lower dose 
of Eliquis, 2.5 mg twice daily. All patients with severe renal impairment (creatinine 
clearance 15-29 ml/min) should receive the lower dose of Eliquis 2.5 mg twice 
daily. Therapy should be continued long term. Treatment of DVT, treatment of PE 
and prevention of recurrent DVT and PE (VTEt): The recommended dose for the 
treatment of acute DVT and treatment of PE is 10 mg taken twice daily for the ﬁrst 
7 days followed by 5 mg taken twice daily. As per available medical guidelines, 
short duration of treatment (at least 3 months) should be based on transient risk 
factors (e.g. recent surgery, trauma, immobilisation). The recommended dose for 
the prevention of recurrent DVT and PE is 2.5 mg taken twice daily. When 
prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should 
be initiated following completion of 6 months of treatment with Eliquis 5 mg twice 
daily or with another anticoagulant. The duration of overall therapy should be 
individualised after careful assessment of the treatment beneﬁt against the risk for 
bleeding. Prevention of VTE (VTEp): elective hip or knee replacement surgery: The 
recommended dose is 2.5 mg taken twice a day. The initial dose should be taken 12 
to 24 hours after surgery. In patients undergoing hip replacement surgery, the 
recommended duration of treatment is 32 to 38 days. In patients undergoing knee 
replacement surgery, the recommended duration of treatment is 10 to 14 days. 
Missed Dose for All Indications: If a dose is missed, Eliquis should be taken 
immediately and then continue with twice daily dose as before. Switching: 
switching treatment from parenteral anticoagulants to Eliquis (and vice versa) can 
be done at the next scheduled dose. These medicinal products should not be 
administered simultaneously. Switching treatment from VKA therapy to Eliquis: 
warfarin or other VKA therapy should be discontinued and Eliquis started when the 
international normalized ratio (INR) is <2. Switching treatment from Eliquis to VKA 
therapy: administration of Eliquis should be continued for at least 2 days after 
beginning VKA therapy. After 2 days of co-administration of Eliquis with VKA 
therapy, an INR should be obtained prior to next scheduled dose of Eliquis. Co-
administration of Eliquis and VKA therapy should be continued until the INR is ≥2. 
Renal impairment: No dose adjustment in mild or moderate renal impairment. 
Eliquis is to be used with caution in severe renal impairment (creatinine clearance 
15-29 mL/min) as there may be an increased risk of bleeding. For the prevention of 
stroke and systemic embolism in patients with NVAF and severe renal impairment, 
patients should receive the lower dose of Eliquis 2.5 mg twice daily. Patients with 
NVAF and serum creatinine ≥1.5 mg/dL (133 micromole/L) associated with age ≥80 
years or body weight ≤60 kg should also receive the lower dose of Eliquis 2.5 mg 
twice daily for stroke/systemic embolism prevention. In patients with creatinine 
clearance <15 mL/min, or in patients undergoing dialysis, there is no clinical 
experience therefore Eliquis is not recommended. Hepatic impairment: 
Contraindicated in patients with hepatic disease associated with coagulopathy and 
clinically relevant bleeding risk. Not recommended in patients with severe hepatic 
impairment. Use with caution in patients with mild or moderate hepatic 
impairment (Child Pugh A or B). No dose adjustment is required in patients with 
mild or moderate hepatic impairment. Use with caution in patients with elevated 
liver enzymes (ALT/AST >2 x ULN) or total bilirubin ≥1.5 x ULN. Prior to initiating 
Eliquis, liver function testing should be performed. Cardioversion (NVAF): Patients 
can stay on Eliquis while being cardioverted. Paediatric population: Eliquis is not 
recommended in children and adolescents below the age of 18. 
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the 
excipients listed in SmPC, active clinically signiﬁcant bleeding, hepatic disease 
associated with coagulopathy and clinically relevant bleeding risk, lesion or 
condition if considered a signiﬁcant risk factor for major bleeding (refer to SmPC). 
Concomitant treatment with any other anticoagulant agent except under speciﬁc 
circumstances of switching anticoagulant therapy or when unfractionated heparin 
is given at doses necessary to maintain an open central venous or arterial catheter 
(refer to SmPC). SPECIAL WARNINGS AND PRECAUTIONS: Haemorrhage risk: 
Carefully observe for signs of bleeding. Use with caution in conditions with 
increased risk of haemorrhage. Discontinue administration if severe haemorrhage 
occurs. Interaction with other medicinal products affecting haemostasis: 
Concomitant treatment with any other anticoagulant is contraindicated (see 
contraindications). The concomitant use of Eliquis with antiplatelet agents 
increases the risk of bleeding. Care is to be taken if patients are treated 
concomitantly with non-steroidal anti-inﬂammatory drugs (NSAIDs), including 
acetylsalicylic acid. Following surgery, other platelet aggregation inhibitors are not 
recommended concomitantly with Eliquis. In patients with atrial ﬁbrillation and 
conditions that warrant mono or dual antiplatelet therapy, a careful assessment of 
the potential beneﬁts against the potential risks should be made before combining 
this therapy with Eliquis. Use of thrombolytic agents for the treatment of acute 
ischemic stroke: there is very limited experience with the use of thrombolytic 
agents for the treatment of acute ischemic stroke in patients administered Eliquis. 
Patients with prosthetic heart valves: safety and efficacy of Eliquis have not been 
studied in patients with prosthetic heart valves, with or without atrial ﬁbrillation. 
Therefore, the use of Eliquis is not recommended in this setting. Surgery and 
invasive procedures: Eliquis should be discontinued at least 48 hours prior to 
elective surgery or invasive procedures with a moderate or high risk of bleeding. This 
includes interventions for which the probability of clinically signiﬁcant bleeding 
cannot be excluded or for which the risk of bleeding would be unacceptable. Eliquis 
should be discontinued at least 24 hours prior to elective surgery or invasive 
procedures with a low risk of bleeding. This includes interventions for which any 
bleeding that occurs is expected to be minimal, non-critical in its location or easily 
controlled. If surgery or invasive procedures cannot be delayed, appropriate caution 
should be exercised, taking into consideration an increased risk of bleeding. This risk 
of bleeding should be weighed against the urgency of intervention. Eliquis should 
be restarted after the invasive procedure or surgical intervention as soon as possible 
provided the clinical situation allows and adequate haemostasis has been 
established (see SmPC). Temporary discontinuation: Discontinuing anticoagulants, 
including Eliquis, for active bleeding, elective surgery, or invasive procedures places 
patients at an increased risk of thrombosis. Lapses in therapy should be avoided 
and if anticoagulation with Eliquis must be temporarily discontinued for any reason, 
therapy should be restarted as soon as possible. Spinal/epidural anaesthesia or 
puncture: When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/
epidural puncture is employed, patients treated with antithrombotic agents for 
prevention of thromboembolic complications are at risk of developing an epidural 
or spinal haematoma which can result in long-term or permanent paralysis. The 
risk of these events may be increased by the post-operative use of indwelling 
epidural catheters or the concomitant use of medicinal products affecting 
haemostasis. Indwelling epidural or intrathecal catheters must be removed at least 
5 hours prior to the ﬁrst dose of Eliquis. The risk may also be increased by traumatic 
or repeated epidural or spinal puncture. Patients are to be frequently monitored for 
signs and symptoms of neurological impairment (e.g., numbness or weakness of 
the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent 
diagnosis and treatment is necessary. Prior to neuraxial intervention the physician 
should consider the potential beneﬁt versus the risk in anticoagulated patients or in 
patients to be anticoagulated for thromboprophylaxis. There is no clinical 
experience with the use of Eliquis with indwelling intrathecal or epidural catheters. 
In case there is such need and based on the general PK characteristics of Eliquis, a 
time interval of 20-30 hours (i.e. 2 x half-life) between the last dose of Eliquis and 
catheter withdrawal should elapse, and at least one dose should be omitted before 
catheter withdrawal. The next dose of Eliquis may be given at least 5 hours after 
catheter removal. As with all newer anticoagulant medicinal products, experience 
with neuraxial blockade is limited and extreme caution is therefore recommended 
when using Eliquis in the presence of neuraxial blockade. Haemodynamically 
unstable PE patients or patients who require thrombolysis or pulmonary 
embolectomy: Eliquis is not recommended as an alternative to unfractionated 
heparin in patients with pulmonary embolism who are haemodynamically 
unstable or may receive thrombolysis or pulmonary embolectomy since the safety 
and efficacy of Eliquis have not been established. Patients with active cancer: 
efficacy and safety of Eliquis in the treatment of DVT, treatment of PE and 
prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not 
been established. Renal impairment: see dosage and administration section. 
Elderly patients: increasing age may increase haemorrhagic risk. Also, the co-
administration of Eliquis with ASA in elderly patients should be used cautiously 
because of a potentially higher bleeding risk. Body weight: low body weight (< 60 
kg) may increase haemorrhagic risk. Hepatic impairment: see dosage and 
administration section. Interaction with Inhibitors of CYP3A4 and P-gp: The use of 
Eliquis is not recommended in patients receiving concomitant systemic treatment 
with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., 
ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease 
inhibitors (e.g., ritonavir). These medicinal products may increase Eliquis exposure 
by 2-fold or greater in the presence of additional factors that increase Eliquis 
exposure (e.g. severe renal impairment). Interaction with Inducers of CYP3A4 and 
P-gp: Eliquis should not be used for the treatment of DVT and PE in patients 
receiving concomitant systemic treatment with strong inducers of both CYP3A4 
and P-gp since efficacy may be compromised. In patients receiving concomitant 
systemic treatment with strong inducers of both CYP3A4 and P-gp, Eliquis should 
be used with caution for the prevention of VTE in elective hip or knee replacement 
surgery, for the prevention of stroke and systemic embolism in patients with NVAF 
and for the prevention of recurrent DVT and PE, though no dose adjustment for 
Eliquis is required during concomitant therapy with such medicinal products. Hip 
fracture surgery: Eliquis has not been studied in clinical trials in patients undergoing 
hip fracture surgery to evaluate efficacy and safety in these patients. Therefore, it is 
not recommended in these patients. Laboratory parameters: Clotting tests (PT, INR, 
and aPTT) are affected as expected by the mechanism of action of apixaban. 
Changes observed in these clotting tests at the expected therapeutic dose are small 
and subject to a high degree of variability (see SmPC). Information about excipients: 
Eliquis contains lactose. Patients with galactose intolerance, the Lapp lactase 
deﬁciency or glucose-galactose malabsorption should not take Eliquis. DRUG 
INTERACTIONS: Medicinal products associated with serious bleeding are not 
recommended concomitantly with Eliquis, such as: thrombolytic agents, GPIIb/IIIa 
receptor antagonists, thienopyridines (e.g. clopidogrel), dipyridamole, dextran and 
sulﬁnpyrazone. Due to an increased bleeding risk, concomitant treatment with any 
other anticoagulants is contraindicated. Administration of activated charcoal 
reduces Eliquis exposure. Also see contraindications and special warnings and 
precautions section; Consult SmPC (contraindications, special warnings and 
precautions and drug interactions) for full details on interactions. PREGNANCY 
AND LACTATION: Pregnancy: Not recommended during pregnancy. Breastfeeding: 
Discontinue breastfeeding or discontinue Eliquis therapy. UNDESIRABLE EFFECTS: 
Increased risk of occult or overt bleeding from any tissue or organ, which may result 
in post haemorrhagic anaemia. The signs, symptoms, and severity will vary 
according to the location and degree or extent of the bleeding. Prevention of VTE in 
adult patients who have undergone elective hip or knee replacement surgery 
(VTEp): Common (≥1/100 to <1/10): anaemia, haemorrhage, haematoma, nausea, 
contusion. Uncommon (≥1/1,000 to <1/100): thrombocytopenia; speciﬁc 
haemorrhage such as gastrointestinal, post procedural, incision site, operative; 
haematochezia. Rare (≥1/10,000 to <1/1,000): hypersensitivity, allergic oedema 
and anaphylaxis; speciﬁc haemorrhage such as eye (including conjunctival), rectal, 
muscle; haemoptysis. Prevention of stroke and systemic embolism in adult patients 
with NVAF, with one or more risk factors (NVAF): Common (≥1/100 to <1/10): 
speciﬁc haemorrhage such as eye (including conjunctival), gastrointestinal, rectal; 
haemorrhage, haematoma, epistaxis, gingival bleeding, haematuria, contusion. 
Uncommon (≥1/1,000 to <1/100): hypersensitivity, allergic oedema and 
anaphylaxis; speciﬁc haemorrhage such as brain, intra-abdominal, abnormal 
vaginal, urogenital, traumatic, post procedural, incision site; haemoptysis, 
haematochezia. Rare (≥1/10,000 to <1/1,000): speciﬁc haemorrhage such as 
respiratory tract, retroperitoneal. Treatment of DVT and PE, and prevention of 
recurrent DVT and PE (VTEt): Common (≥1/100 to <1/10): haemorrhage, 
haematoma, epistaxis; speciﬁc haemorrhage such as gastrointestinal, rectal; 
gingival bleeding, haematuria, contusion. Uncommon (≥1/1,000 to <1/100): 
speciﬁc haemorrhage such as eye (including conjunctival), abnormal vaginal, 
urogenital, traumatic, post procedural, incision site; haemoptysis, haematochezia. 
Rare (≥1/10,000 to <1/1,000): speciﬁc haemorrhage such as brain, respiratory 
tract. Please refer to the SmPC for further details of adverse reactions including 
other types of haemorrhage. LEGAL CATEGORY: POM. PACKAGE QUANTITIES AND 
BASIC NHS PRICE: Carton of 10 ﬁlm-coated tablets 2.5mg £9.50, 20 ﬁlm-coated 
tablets 2.5mg £19.00, 60 ﬁlm-coated tablets 2.5mg £57.00, 56 ﬁlm-coated tablets 
5mg £53.20, 28 ﬁlm-coated tablets 5mg £26.60. MARKETING AUTHORISATION 
NUMBERS: EU/1/11/691/001-3, EU/1/11/691/008, EU/1/11/691/014 
MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb/Pﬁzer EEIG, BMS 
House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH. 
Telephone: 0800-731-1736. DATE OF PI PREPARATION: March 2016 
432UK1600117-01-01 ELQ1118should consider the potential beneﬁt versus the 
risk in anticoagulated patients or in patients to be anticoagulated for 
thromboprophylaxis. There is no clinical experience with the use of Eliquis with 
indwelling intrathecal or epidural catheters. In case there is such need and based on 
the general PK characteristics of Eliquis, a time interval of 20-30 hours (i.e. 2 x 
half-life) between the last dose of Eliquis and catheter withdrawal should elapse, 
and at least one dose should be omitted before catheter withdrawal. The next dose 
of Eliquis may be given at least 5 hours after catheter removal. As with all newer 
anticoagulant medicinal products, experience with neuraxial blockade is limited 
and extreme caution is therefore recommended when using Eliquis in the presence 
of neuraxial blockade. Haemodynamically unstable PE patients or patients who 
require thrombolysis or pulmonary embolectomy: Eliquis is not recommended as 
an alternative to unfractionated heparin in patients with pulmonary embolism who 
are haemodynamically unstable or may receive thrombolysis or pulmonary 
embolectomy since the safety and efficacy of Eliquis have not been established. 
Patients with active cancer: efficacy and safety of Eliquis in the treatment of DVT, 
treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with 
active cancer have not been established. Renal impairment: see dosage and 
administration section. Elderly patients: increasing age may increase haemorrhagic 
risk. Also, the co-administration of Eliquis with ASA in elderly patients should be 
used cautiously because of a potentially higher bleeding risk. Body weight: low body 
weight (< 60 kg) may increase haemorrhagic risk. Hepatic impairment: see dosage 
and administration section. Interaction with Inhibitors of CYP3A4 and P-gp: The use 
of Eliquis is not recommended in patients receiving concomitant systemic 
treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-
antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and 
HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase 
Eliquis exposure by 2-fold or greater in the presence of additional factors that 
increase Eliquis exposure (e.g. severe renal impairment). Interaction with Inducers 
of CYP3A4 and P-gp: Eliquis should not be used for the treatment of DVT and PE in 
patients receiving concomitant systemic treatment with strong inducers of both 
CYP3A4 and P-gp since efficacy may be compromised. In patients receiving 
concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp, 
Eliquis should be used with caution for the prevention of VTE in elective hip or knee 
replacement surgery, for the prevention of stroke and systemic embolism in 
patients with NVAF and for the prevention of recurrent DVT and PE, though no dose 
adjustment for Eliquis is required during concomitant therapy with such medicinal 
products. Hip fracture surgery: Eliquis has not been studied in clinical trials in 
patients undergoing hip fracture surgery to evaluate efficacy and safety in these 
patients. Therefore, it is not recommended in these patients. Laboratory 
parameters: Clotting tests (PT, INR, and aPTT) are affected as expected by the 
mechanism of action of apixaban. Changes observed in these clotting tests at the 
expected therapeutic dose are small and subject to a high degree of variability (see 
SmPC). Information about excipients: Eliquis contains lactose. Patients with 
galactose intolerance, the Lapp lactase deﬁciency or glucose-galactose 
malabsorption should not take Eliquis. DRUG INTERACTIONS: Medicinal products 
associated with serious bleeding are not recommended concomitantly with Eliquis, 
such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g. 
clopidogrel), dipyridamole, dextran and sulﬁnpyrazone. Due to an increased 
bleeding risk, concomitant treatment with any other anticoagulants is 
contraindicated. Administration of activated charcoal reduces Eliquis exposure. Also 
see contraindications and special warnings and precautions section; Consult SmPC 
(contraindications, special warnings and precautions and drug interactions) for full 
details on interactions. PREGNANCY AND LACTATION: Pregnancy: Not 
recommended during pregnancy. Breastfeeding: Discontinue breastfeeding or 
discontinue Eliquis therapy. UNDESIRABLE EFFECTS: Increased risk of occult or 
overt bleeding from any tissue or organ, which may result in post haemorrhagic 
anaemia. The signs, symptoms, and severity will vary according to the location and 
degree or extent of the bleeding. Prevention of VTE in adult patients who have 
undergone elective hip or knee replacement surgery (VTEp): Common (≥1/100 to 
<1/10): anaemia, haemorrhage, haematoma, nausea, contusion. Uncommon 
(≥1/1,000 to <1/100): thrombocytopenia; speciﬁc haemorrhage such as 
gastrointestinal, post procedural, incision site, operative; haematochezia. Rare 
(≥1/10,000 to <1/1,000): hypersensitivity, allergic oedema and anaphylaxis; 
speciﬁc haemorrhage such as eye (including conjunctival), rectal, muscle; 
haemoptysis. Prevention of stroke and systemic embolism in adult patients with 
NVAF, with one or more risk factors (NVAF): Common (≥1/100 to <1/10): speciﬁc 
haemorrhage such as eye (including conjunctival), gastrointestinal, rectal; 
haemorrhage, haematoma, epistaxis, gingival bleeding, haematuria, contusion. 
Uncommon (≥1/1,000 to <1/100): hypersensitivity, allergic oedema and 
anaphylaxis; speciﬁc haemorrhage such as brain, intra-abdominal, abnormal 
vaginal, urogenital, traumatic, post procedural, incision site; haemoptysis, 
haematochezia. Rare (≥1/10,000 to <1/1,000): speciﬁc haemorrhage such as 
respiratory tract, retroperitoneal. Treatment of DVT and PE, and prevention of 
recurrent DVT and PE (VTEt): Common (≥1/100 to <1/10): haemorrhage, 
haematoma, epistaxis; speciﬁc haemorrhage such as gastrointestinal, rectal; 
gingival bleeding, haematuria, contusion. Uncommon (≥1/1,000 to <1/100): 
speciﬁc haemorrhage such as eye (including conjunctival), abnormal vaginal, 
urogenital, traumatic, post procedural, incision site; haemoptysis, haematochezia. 
Rare (≥1/10,000 to <1/1,000): speciﬁc haemorrhage such as brain, respiratory 
tract. Please refer to the SmPC for further details of adverse reactions including 
other types of haemorrhage. LEGAL CATEGORY: POM. PACKAGE QUANTITIES AND 
BASIC NHS PRICE: Carton of 10 ﬁlm-coated tablets 2.5mg £9.50, 20 ﬁlm-coated 
tablets 2.5mg £19.00, 60 ﬁlm-coated tablets 2.5mg £57.00, 56 ﬁlm-coated tablets 
5mg £53.20, 28 ﬁlm-coated tablets 5mg £26.60. MARKETING AUTHORISATION 
NUMBERS: EU/1/11/691/001-3, EU/1/11/691/008, EU/1/11/691/014 
MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb/Pﬁzer EEIG, BMS 
House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH. 
Telephone: 0800-731-1736. DATE OF PI PREPARATION: March 2016 
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Adverse events should be reported. Reporting forms and 
information can be found at www.mhra.gov.uk/yellowcard.  
Adverse events should also be reported to Bristol-Myers 
Squibb Pharmaceuticals Ltd Medical Information on  
0800 731 1736 or medical.information@bms.com
Help protect your patients with non-valvular atrial fibrillation (NVAF) against stroke / systemic embolism
Reference: 1. Granger CB et al. N Engl J Med 2011; 365: 981–992.
Date of preparation: May 2017    Job code: 432UK1700548-01
ONLY ELIQUIS®  
CONNECTS BOTH  
IN PATIENTS  
WITH NVAF
ELIQUIS is the only factor Xa inhibitor that  
has demonstrated superior risk reduction in 
stroke / systemic embolism with significantly  
less major bleeding vs. warfarin1
SUPERIORITY
demonstrated on
STROKE / 
SYSTEMIC
EMBOLISM
vs. warfarin1
SUPERIORITY
demonstrated on 
MAJOR 
BLEEDING
vs. warfarin1
8Preliminary Programme
08:00 – 09:00 Grand Ballroom Lobby and Pre-Function Lounge
 Registration, Exhibition and Refreshments
09:00 – 10:30 Plenary 1 
Grand Ballroom Advancing the Stroke Pathway in Northern Ireland 
Sub-Section 3
  Chair: Nicola Moran (Clinical Physiotherapy Specialist in Stroke, 
Belfast Health and Social Care Trust)
09:00 – 09:05 Welcome and Introductions
09:05 – 09:25 Future Prooﬁng Stroke Services in Northern Ireland 
  Dr Brid Farrell (Assistant Director, Service Development, Safety 
and Quality)
09:25 – 09:45  Centralising to a seven day acute stroke service in 
Greater Manchester – lessons learnt 
Sarah Rickard (Manager, Greater Manchester Stroke Operational 
Delivery Network) and Dr Jane Molloy (Consultant Neurologist, 
Greater Manchester Stroke ODN)
09:45 – 10:20  Stroke Survivors perspective
 Unmet needs of stroke survivors and their carers 
  Stroke survivors and carers will give their perspective, focusing 
on long term rehabilitation and care needs and the interventions 
required in both community and residential settings 
10:20 – 10:30 Questions and Answers
10:30 – 11:15 Exhibition, Posters and Refreshments
911:15 – 12:30 Parallel 1A 
Grand Ballroom Management of Cardioembolic Stroke 
Sub-Section 3
  Chair: Dr Stephen Todd (Consultant Geriatrician, Western 
Health and Social Care Trust and Honorary Lecturer, Queen’s 
University Belfast)
11:15 – 11:20 Welcome and Introductions
11:20 – 11:35 When should AF be ablated? 
  Dr Conor McCann (Consultant Cardiologist / Electrophysiologist 
Belfast Trust)
11:35 – 11:50  PFO Closure and the role of left atrial appendage 
occlusion 
Dr Mark Spence (Consultant Cardiologist, Royal Victoria Hospital, 
Belfast Trust and Honorary Senior Lecturer, Queen’s University 
Belfast)
11:50 – 12:05  DOACs – the story so far!
  Dr Gary Benson (Consultant Haematologist, Belfast City Hospital, 
Belfast Health and Social Care Trust)
12:05 – 12:20  DOACs: Getting it Right!
  Leona Rodgers and Dr Roisin Healy (Pharmacist, Stroke  
Unit BHSCT)
12:20 – 12:30 Questions and Answers
11:15 – 12:30 Parallel 1B 
Grand Ballroom Physical and Psychosexual Effects after Stroke 
Sub-Section 1
  Chair: Dr Shelley McKeown (Stroke Services, Western Health & 
Social Care Trust)
11:15 – 11:20 Welcome and Introductions
11:20 – 11:35  Enabling people after stroke to retain intimate 
relationships 
Dr Neal Cook (Reader, School of Nursing, Ulster University)
11:35 – 11:50  The development of spasticity and contractures after 
stroke. Can we stop them and how might we do this? 
Cameron Lindsey (Physiotherapist, South Eastern Trust,  
Keele University)
Kindly Sponsored by
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11:50 – 12:05  Let’s talk about aphasia; current evidence and 
collaborative working 
Professor Marian Brady (Professor Stroke Care & Rehabilitation, 
NMAHP Research Unit)
12:05 – 12:20  Post-stroke upper limb rehabilitation – next steps 
Dr Nick Ward (Reader in Clinical Neurology & Honorary Consultant 
Neurologist, Sobell Department of Motor Neuroscience UCL Institute 
of Neurology and National Hospital for Neurology  
and Neurosurgery)
12:20 – 12:30 Questions and Answers
12:30 – 13:30 Lunch, Exhibition and Poster Viewing
13:30 – 15:00 Parallel 2A 
Grand Ballroom Rehabilitation, enablement and enhancing quality of  
Sub-Section 3 life of nursing home residents post stroke
  Chair: Dr Liz Laird (Lecturer of Nursing, Ulster University)
13:30 – 13:35 Welcome and Introductions
13:35 – 14:00  My Home Life: Challenges and Opportunities in 
Improving Quality of Stroke Care in Nursing and 
Residential Homes 
Professor Assumpta Ryan (Professor of Ageing and Health,  
Ulster University)
14:00 – 14:25  In-reach rehabilitation for person-centred care 
Mandy Ellis (Practice Development Nurse)
14:25 – 14:50  Exploring the value of 6 month reviews in care home 
settings to ask: are we meeting the needs of stroke 
survivors in care homes? 
Dr Emma Patchick (Research Associate for GM-CLAHRC  
Stroke Programme)
14:50 – 15:00 Questions and Answers
Kindly Sponsored by
11
13:30 – 15:00 Parallel 2B 
Grand Ballroom High Scoring Abstracts 
Sub-Section 1
  Chair: Dr Michael McCormick (Consultant Stroke Physician, 
Craigavon Area Hospital, Southern Health and Social Care Trust)
13:30 – 13:35 Welcome and Introductions
13:35 – 13:47  Stroke Prevention Rehabilitation Intervention Trial of 
Exercise (SPRITE) - A Randomised Feasibility Study
  Dr Neil Heron (NIHR Clinical Fellow in GP and Sport and 
Exercise Medicine, Centre for Public Health, Queen’s  
University Belfast)
13:47 – 13:59  Effect of IQoro® training on impaired postural 
control and oropharyngeal motor function in patients 
with dysphagia after stroke
  Dr Mary Hägg (Head of Department, Speech and Swallowing 
Centre, ENT Faculty, Hudiksvall Hospital, Sweden)
13:59 – 14:18  Post-Stroke Ankle-Foot Orthoses: Examining Referral 
Trends in the Scottish Multi-Disciplinary Team
  Eileen Morrow (Orthotist, Nufﬁeld Orthopaedic Centre, Oxford)
14:18 – 14:30  Head Position in Stroke Trial (HeadPoST) results: 
implications for clinical practice
  Dr Liz Lightbody (Reader in Health Services Research, School of 
Nursing, University of Central Lancashire)
14:30 – 14:42  Outcomes after thrombectomy in Belfast: a 
comparison of drip and ship versus mothership 
paradigms
 Dr Karen Adams (Specialty Doctor, Stroke Unit, RVH)
14:42 - 14:54  Untreated visual deﬁcits and length of stroke 
inpatient admissions: is there a link?
  David Wright (Specialist Orthoptist, Western Health & Social  
Care Trust)
14:54 – 15:00 Questions and Answers
15:00 – 15:30 Exhibition, Posters and Refreshments
Kindly Sponsored by
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15:30 – 17:00 Plenary 2 
Grand Ballroom Reading between the guidelines  
Sub-Section 3
  Chairs: Dr Patricia Gordon (Consultant Physician, Belfast Health 
and Social Care Trust) and Nicola Moran (Clinical Physiotherapy 
Specialist in Stroke, Belfast Health and Social Care Trust)
15:30 – 15:35 Welcome, Introductions and Prize Giving
15:35 – 15:50  Reading between the guidelines – acute stroke and 
TIA 
Professor Peter Langhorne (Chair of UK Stroke Forum,  
Professor of Stroke Care, University of Glasgow)
15:50 – 16:05  What guidance from clinical guidelines on the 
provision of SLT for aphasia 
Professor Marian Brady (Professor Stroke Care & Rehabilitation, 
NMAHP Research Unit)
16:05 – 16:20 Psychological interventions after stroke 
  Dr Fiadhnait O’Keeffe PhD, DClinPsyc (Senior Clinical 
Neuropsychologist National Rehabilitation Hospital, Dun 
Laoghaire, Co. Dublin)
16:20 – 16:35 Update on Thrombectomy and from Belfast Trust 
  Dr Ian Rennie (Consultant Interventional Neuroradiologist,  
Belfast Health and Social Care Trust)
16:35 – 16:50 RCPCH Clinical Guideline, Stroke in Childhood 
  An evidence-based guideline for diagnosis, 
management, and rehabilitation 
Dr Neil Baldwin (Consultant Stroke Physician, Royal Devon & 
Exeter Foundation Trust)
16:50 – 17:00 Questions and Answers 
 Close and Final Remarks
17:00  Conference Ends
17:00  NIMAST AGM
 Drinks kindly sponsored by
Kainos Evolve and 
InTouch Health: 
partnering to empower 
high-quality, efficient, 
effective stroke care.
Find out more at 
kainosevolve.com and 
intouchhealth.com
Proud sponsors of the NI Stroke Conference 
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Stand 14 – Allergan
Email: ukcustomerservices@allergan.com    Website: www.allergan.co.uk
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health 
care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and 
medical devices that enable people to live life to its greatest potential – to see more clearly, move more 
freely, express themselves more fully. The Company employs approximately 8,000 people worldwide and 
operates state-of-the-art R&D facilities and world-class manufacturing plants.  
In addition to its discovery-to-development research organization, Allergan has global marketing and sales 
capabilities with a presence in more than 100 countries.
Stand 4 – Bayer
Email: communications.ukireland@bayer.com    Website: www.bayer.com
Bayer aims to improve people’s quality of life with our products. To achieve this, we concentrate on the 
research and development of innovative drugs and novel therapeutic approaches. At the same time, we 
are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses the 
experience it has gained from over a century in the business.
Stand 1 – BMS/Pﬁzer Alliance
Email:  jacqueline.barbour@bms.com    Website: www.eliquis.co.uk
About the Bristol-Myers Squibb/Pﬁzer Collaboration
In 2007, Bristol-Myers Squibb and Pﬁzer entered into a worldwide collaboration to develop and
commercialise an oral anticoagulant discovered by Bristol Myers Squibb. This global alliance
combines Bristol Myers Squibb’s long-standing strengths in cardiovascular drug development and
commercialisation with Pﬁzer’s global scale and expertise in this ﬁeld.
Exhibitors
Stand 17 – Capita
Email: piprecruitment@capita.co.uk    Website: www.capita.com
Capita PIP are currently recruiting for Nurses, Paramedics, Occupational Therapists & Physiotherapists to 
work as Disability Assessors. We currently have roles available in Wales, East Midlands, West Midlands & 
Northern Ireland. We are recruiting for full & part time permanent roles paying £34,000 to £38,000 per 
annum & contractor roles paying £95 per report. For more information please come & speak to some of 
our existing Disability Assessors on the stand or email piprecruitment@capita.co.uk
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Stand 8 – Daiichi Sankyo
Email: Una.Lordan@daiichi-sankyo.co.uk    Website: www.daiichi-sankyo.co.uk
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to 
address diversiﬁed, unmet medical needs of patients in both mature and emerging markets.
With over 100 years of scientiﬁc expertise and a strong portfolio of medicines for hypertension, 
thrombotic disorders and oncology. For more information, please visit our website.
Stand 3 – Kainos Evolve / InTouch Health
Email: evolve@kainosevolve.com    Website: www.kainosevolve.com
Kainos Evolve® is part of Kainos Group plc, which employs over 1000 staff and is headquartered in 
Belfast, with ofﬁces in UK, Ireland, USA and Poland. The Evolve Integrated Care Platform is enabling 
healthcare providers to bring their patient information together, across teams and organizations, enabling 
better-informed care, including access for the patient and their carers. The award-winning Evolve Electronic 
Medical Records (EMR) platform automates the creation, capture and handling of medical casenotes 
allowing healthcare providers to deliver better patient safety and quality of care. Evolve is a leader in 
Mobile-Enabled Healthcare software for iOS, transforming clinical outcomes for patients and healthcare 
providers.
Website: www.intouchhealth.com 
InTouch Health provides technology-enabled services to healthcare providers for the delivery of high-quality 
clinical care virtually anywhere, anytime. The InTouch Telehealth Network empowers healthcare systems to 
deploy telehealth applications across their own enterprise, and into other care sites, such as non-afﬁliated 
hospitals, rehab centers, long-term care, clinics and homes. InTouch Health also offers physician services to 
assist healthcare systems in meeting their telehealth demands, and to address physician shortages.
Stand 5 – Medtronic
Email: ann.blythman@medtronic.com    Website: www.medtronic.com
As a global leader in medical technology, services and solutions, Medtronic improves the lives and 
health of millions of people each year. We use our deep clinical, therapeutic, and economic expertise 
to address the complex challenges faced by healthcare systems today. That’s why we’re committed 
to partnering in new ways and developing powerful solutions that deliver better patient outcomes. 
Medtronic is committed to providing evidence based technology to treat Neurovascular disease 
providing solutions to hemorrhagic and Ischaemic Stroke patients. Let’s take healthcare Further, 
Together. Learn more at Medtronic.com.
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Stand 6 – Nestlé
Email: stella.campbell@uk.nestle.com    Website: www.nestlehealthscience.com
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in 
advancing the role of nutritional therapy to change the course of health for consumers, patients and 
our partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs, targets a 
number of health areas, such as inborn errors of metabolism, paediatric and acute care, obesity care, 
healthy ageing, and gastrointestinal and brain health. Through investing in innovation and leveraging 
leading edge science, we bring forward innovative nutritional therapies with proven clinical, health 
economic value and quality of life beneﬁts. Nestlé Health Science employs around 3,000 people 
worldwide and is headquartered near Lausanne, Switzerland. For more information, please visit our 
website. 
Stand 18 – Nihon Kohden UK Ltd
Email: info@nihonkohden.co.uk    Website: Nihonkohden.net
NIHON KOHDEN is one of Japan’s leading players in medical technology development and 
manufacturing, we are renowned the world over for innovation, reliability and engineering quality, 
and have been manufacturing medical devices for more than 60 years. Nihon Kohden and apoplex 
medical technologies collaborate on game-changing stroke solutions. A patient’s 6-lead ECG 
waveforms from a Nihon Kohden patient monitor are automatically, continuously transferred to 
apoplex medical technologies as soon as the patient is monitored in a hospital. After automatic 
analysis on their servers, clinicians receive reliable Stroke Risk Analysis reports the next morning to use 
as a basis for therapy decisions and further treatment options. 
Stand 2 – MYoroface
Email: terry.morris@myoroface.com    Website: www.iqoro.com
MYoroface is the company that has researched, developed, produced, patented and  
registered IQoro®.
IQoro® helps people after stroke with problems with swallowing, facial paralysis, speech, Hiatus 
hernia, snoring or sleep apnoea, and more. IQoro® is a new and unique neuromuscular treatment 
method that requires just 30 seconds’ exercise, three times per day.
www.iqoro.com is now a comprehensive knowledge hub where everything from the symptoms, to the 
underlying causes of post-stroke conditions are described, as well as how IQoro® treats and gets to 
the bottom of the fundamental problem. Dozens of patient stories give hope and inspiration.
Breathe. Eat. Smile. Talk.
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Stand C – Northern Ireland Chest Heart & Stroke
Email: rstarkey@nichs.org.uk    Website: www.nichs.org.uk
NICHS is the local charity for the care and prevention of chest, heart and stroke illnesses. We work with 
people who have these conditions and their families, offering practical and emotional support at what 
can be a difﬁcult time in their lives. Our support groups provide an opportunity to share experiences while 
beneﬁtting from a structured programme of activities including rehabilitation, exercise and information. 
We do health promotion in schools, with the homeless and in workplaces. We fund research relating to 
prevention, treatment and care. We campaign at Assembly level for people and families who are affected 
by these conditions.
Stand 7 – NI Clinical Research Network NICRN
Email:  info.NICRN@belfasttrust.hscni.net    Website: www.nicrn.hscni.net 
The Northern Ireland Clinical Research Network Stroke speciality was established in 2008. It is currently led 
by Dr Michael Power of the South Eastern Health and Social Care Trust and Mrs Carolee McLaughlin of the 
Belfast Health and Social Care Trust. We enable the research community, both service users and potential 
investigators to engage with and successfully deliver nationally important clinical trials and other high 
quality research by deploying a cadre of skilled and managed staff across all 5 HSC Trust and at present 
the Network deploys 7 staff members across the Trusts to facilitate the delivery of this research portfolio. 
Engagement is simple and all supporting documentation can be found on our website. So please get in 
touch and see what we can do next.
Stand D - NIMAST
Email: www.nimast.org.uk/contact    Website: www.nimast.org.uk
NIMAST is the only multidisciplinary association for stroke in Northern Ireland and provides a forum for sharing 
best practice, disseminating service improvements and research ﬁndings.  NIMAST also has signiﬁcant inﬂuence 
on stroke service development, guidelines and stroke strategies, through direct co-operation with government, 
HSC and the Public Health Agency.  NIMAST has strong links with stroke groups both in the UK and Ireland, 
including the Stroke Association and the UK Stroke Forum. 
NIMAST can give you the opportunity to engage more fully with stroke service change and implementation, and 
help implement the things that you, as a front line stroke service provider, see as important. 
Our annual conference is the only dedicated multidisciplinary conference in the UK or Ireland.
VISIT OUR NEW WEBSITE & JOIN NIMAST BY REGISTERING ONLINE www.nimast.org.uk
For a small annual subscription of £20, (reduced rate of £10 for students) you can gain full access to online 
discussion forums, links to other relevant sites, service improvement bulletins and conference presentations/ 
slides. You will also beneﬁt from reduced NIMAST/ UKSF conference rates. 
Please note that all current NIMAST members will soon be receiving further notiﬁcation regarding updating their 
membership online.
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Stand 13 – Saebo
Email: ukinfo@saebo.com    Website: www.saebo.com
Saebo UK is a leading distributor of innovative technology for neurological rehabilitation.
We have affordable, evidence based therapy solutions for mobility and function.
Stand 11 – Silverlink Software Limited
Email: info@silverlinksoftware.com    Website: www.silverlinksoftware.com
CaptureStroke is Silverlink’s marketing leading care performance improvement system for stroke services. 
Offering Trusts full ownership of their data and real-time analytics to understand and measure performance 
throughout the care pathway, CaptureStroke forms part of Silverlink’s best-of  -breed modular solution 
portfolio. Silverlink has been a leading software supplier to the NHS for over 20 years, and design solutions 
based on an in-depth knowledge of NHS processes and requirements. Working in close collaboration with 
clinicians, Silverlink offers intuitive, intelligent data solutions that facilitate paperless and mobile working 
that goes beyond basic SSNAP reporting requirements for meaningful insights into Stroke care delivery.
Stand E – Royal College of Speech and Language Therapists
Email: info@rcslt.org    Website: www.rcslt.org
The Royal College of Speech and Language Therapists (RCSLT) is the professional body for speech and 
language therapists in the UK, representing more than 17,000 members (around 500 in Northern Ireland). 
It facilitates and promotes research into the ﬁeld of speech and language therapy – the care for individuals 
with communication, swallowing, eating and drinking difﬁculties. It promotes better education and 
training of speech and language therapists and is responsible for setting and maintaining high standards 
in education, clinical practice and ethical conduct. The RCSLT’S Giving Voice campaign is highlighting 
the importance of speech and language therapy by sharing the life-changing stories of those who have 
beneﬁted from treatment and by demonstrating evidence of speech and language therapists’ efﬁciency and 
value for money. For more information on RCSLT and Giving Voice visit our website.
Stand 19 – Novacor UK Ltd
Email: enquiries@novacor.co.uk    Website: www.novacor.co.uk
R.Test Evoltion 4 – The obvious choice for AF detection from Novacor The R.Test Evolution 4 – Automatic 
ECG Arrhythmia Detection System is a lightweight noninvasive ECG monitor especially effective for 
detecting the presence of AF and PAF over longer durations1. Weighing just (42g) and approximately the 
size of a small matchbox, the R.Test Evolution 4 has become the obvious choice for stroke professionals; 
providing an effective, swift and practical means to capture and identify or conﬁdently exclude AF as a 
cause for stroke.
Visit stand no: 19 today for more information.
Address: Southern Cross Industrial Estate, London Road, Swanley, Kent, BR8 8EE 
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Stand 12 – SSNAP/Royal College of Physicians
Email: stroke@rcplondon.ac.uk    Website: www.rcplondon.ac.uk/ssnap
The Sentinel Stroke National Audit Programme is the single source of stroke data for Northern Ireland. 
The SSNAP Clinical Audit provides regular reports on stroke care at team level, Local Commissioning 
Group (LCG) level and national level to help inform quality improvement.
Stand A – Stroke Association
Email: info@stroke.org.uk    Website: www.stroke.org.uk
Stroke Association is a charity. We believe in life after stroke together we can conquer stroke. We work 
directly with stroke survivors and their families and carers, with health and social care professionals 
and with scientists and researchers. We campaign to improve stroke care and support people to 
make the best recovery they can. We fund research to develop new treatments and ways of preventing 
stroke. The Stroke Helpline (0303 303 3100) provides information and support on stroke. More 
information can be found on our website.
Stand 16 – Stryker
Email: enquiries@stryker.com    Website: www.stryker.com
Stryker is focused on advancing the practice of less invasive stroke therapies through its Complete 
Stroke Care solutions. Stryker is dedicated to providing innovative stroke products and services for 
ischemic and haemorrhagic stroke, and committed to providing clinical education and support to help 
physicians deliver better patient outcomes. Products include: stent retriever, detachable coils, stents, 
balloons, guidewires and microcatheters.
Stand B – The Magic Project
Email: SBRI.PMO@hscni.net    Website: www.magic-pcp.eu
Business Services Organisation (BSO) provides a broad range of regional businesses support functions 
and specialist professional services to the Health and Social Care sector in Northern Ireland. MAGIC is a 
European Commission Co-Funded Pre-Commercial Procurement Project focused on the development of 
ICT based solutions to improve the well-being of patients and optimise the opportunity for recovery post-
stroke. BSO leads and co-ordinates the MAGIC consortium. Other NI participants are the Health and 
Social Care Board, the Public Health Agency, Invest NI and the University of Ulster. Other member states 
involved in the consortium are Ireland, Italy, Finland, Spain, Luxembourg and Denmark.
Indicated for:7 
Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension,  
age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
www.lixiana.co.uk
ONCE-DAILY LIXIANA®      (edoxaban).
References: 1. NICE Technology Appraisal 355. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. September 2015. Available at: www.nice.org.uk/guidance/ta355 
Accessed September 2015. 2. NICE Technology Appraisal 354. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. August 2015. Available at: www.nice.org.uk/guidance/ta354 
Accessed September 2015. 3. Scottish Medicines Consortium. SMC No. (1095/15). edoxaban (Lixiana) for NVAF. Available at: http://www.scottishmedicines.org.uk/files/advice/edoxaban__Lixiana__NVAF_FINAL_
October_2015_Amended_03.11.15.pdf Accessed: May 2016. 4. Scottish Medicines Consortium. SMC No. (1095/15). edoxaban (Lixiana) for NVAF. Available at: http://www.scottishmedicines.org.uk/files/advice/
edoxaban__Lixiana__VTE_FINAL_October_2015_Amended_26.10.15___03.11.15_for_website.pdf Accessed: May 2016. 5. Giugliano RP et al. NEJM 2013;369(22):2093–2104. 6. The Hokusai-VTE Investigators. 
NEJM 2013;369(15):1406–1415. 7. LIXIANA®, Summary of Product Characteristics.
© (2016) Daiichi Sankyo UK Limited. All rights reserved. Date of preparation: May 2017. EDX/17/0105
LIXIANA  (edoxaban) 60 mg/30 mg/15 mg film coated tablets 
See summary of product characteristics prior to prescribing for full 
list of adverse events
Presentation: 60 mg (yellow)/30 mg (pink)/15 mg (orange) edoxaban 
film coated tablets (as tosilate). Indications: Prevention of stroke and 
systemic embolism in adult patients with nonvalvular atrial fibrillation 
(NVAF) with one or more risk factors, such as congestive heart 
failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or 
transient ischaemic attack (TIA) and treatment of deep vein thrombosis 
(DVT) and pulmonary embolism (PE), and prevention of recurrent DVT 
and PE in adults. Posology and method of administration: NVAF – 
The recommended dose is 60 mg edoxaban once daily with or without 
food. Therapy with edoxaban in NVAF patients should be continued 
long term. VTE – The recommended dose is 60 mg edoxaban once 
daily following initial use of parenteral anticoagulant for at least 
5 days with or without food. Duration of therapy (at least 3 months) 
should be based on risk profile of the patient. For NVAF and VTE the 
recommended dose is 30 mg edoxaban once daily in patients with 
one or more of the following clinical factors: moderate or severe renal 
impairment (creatinine clearance (CrCL) 15–50 ml/min), low body 
weight ≤60 kg and/or concomitant use of the following P-glycoprotein 
(P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or 
ketoconazole. The 15 mg dose of edoxaban is not indicated as 
monotherapy, and should only be used during a switch from edoxaban 
to VKA (see SmPC for full details). If a dose of edoxaban is missed, 
the dose should be taken immediately and then continued once 
daily on the following day. Contraindications: Hypersensitivity to 
the active substance or to any of the excipients; clinically significant 
active bleeding. Hepatic disease associated with coagulopathy and 
clinically relevant bleeding risk. Lesion or condition, if considered to be 
a significant risk for major bleeding. This may include current or recent 
gastrointestinal (GI) ulceration, presence of malignant neoplasms 
at high risk of bleeding, recent brain or spinal injury, recent brain, 
spinal or ophthalmic surgery, recent intracranial haemorrhage, known 
or suspected oesophageal varices, arteriovenous malformations, 
vascular aneurysms or major intraspinal or intracerebral vascular 
abnormalities. Uncontrolled severe hypertension. Concomitant 
treatment with any other anticoagulants e.g. UFH, low molecular weight 
heparins, heparin derivatives (fondaparinux, etc.), VKA or NOACs 
except under specific circumstances of switching oral anticoagulant 
therapy or when UFH is given at doses necessary to maintain an open 
central venous or arterial catheter. Pregnancy and breastfeeding. 
Special warnings and precautions for use: Haemorrhagic risk: Use 
with caution in patients with increased risk of bleeding such as elderly 
on ASA and should be discontinued if severe haemorrhage occurs. 
The anticoagulant effect of edoxaban cannot be reliably monitored with 
standard laboratory testing. A specific anticoagulant reversal agent for 
edoxaban is not available. Haemodialysis does not significantly clear 
edoxaban. Renal impairment: Renal function should be assessed prior 
to initiation of edoxaban and afterwards when clinically indicated. Not 
recommended in patients with end-stage renal disease or on dialysis. 
Renal function and NVAF: A trend towards decreasing efficacy with 
increasing creatinine clearance was observed for edoxaban compared 
to well-managed warfarin. Edoxaban should only be used in patients 
with NVAF and high creatinine clearance after a careful benefit risk 
evaluation. Hepatic impairment: Not recommended in patients with 
severe hepatic impairment and should be used with caution in patients 
with mild or moderate hepatic impairment. Edoxaban should be used 
with caution in patients with elevated liver enzymes (ALT/AST >2 x ULN) 
or total bilirubin ≥1.5 x ULN. Surgery or other interventions: discontinue 
edoxaban at least 24 hours before the procedure. If the procedure 
cannot be delayed, the increased risk of bleeding should be weighed 
against the urgency of the procedure. Edoxaban should be restarted as 
soon as haemostasis is achieved. Prosthetic heart valves and moderate 
to severe mitral stenosis: Not recommended. Haemodynamically 
unstable PE patients or patients who require thrombolysis or pulmonary 
embolectomy : Not recommended. Patients with active cancer : Not 
recommended. Drug interactions: The P-gp inhibitors ciclosporin, 
dronedarone, erythromycin, or ketoconazole result in increased 
concentration of edoxaban and a dose reduction of 30 mg is required. 
Edoxaban should be used with caution with concomitant P-gp 
inducers (e.g. phenytoin, carbamazepine, phenobarbitol or St John’s 
Wort). Concomitant high dose ASA (325 mg) or chronic NSAIDs is not 
recommended. There is very limited experience with dual antiplatelet 
therapy or fibrinolytic agents. Undesirable effects: Common: 
anaemia, epistaxis, lower GI haemorrhage, upper GI haemorrhage, 
oral/pharyngeal haemorrhage, nausea, blood bilirubin increased, 
gamma GT increased, cutaneous soft tissue haemorrhage, rash, 
pruritus, macroscopic haematuria/urethral haemorrhage, vaginal 
haemorrhage, puncture site haemorrhage, liver function test abnormal. 
Uncommon: hypersensitivity, intracranial haemorrhage (ICH), 
intraocular haemorrhage, other haemorrhage, haemoptysis, surgical 
site haemorrhage. Rare: anaphylactic reaction, allergic oedema, 
subarachnoid haemorrhage, pericardial haemorrhage, retroperitoneal 
haemorrhage, intramuscular haemorrhage (no compartment 
syndrome), intra-articular haemorrhage, subdural haemorrhage, 
procedural haemorrhage. Legal category: POM. Package 
quantities and basic NHS costs: 60 mg/30 mg – 28 tablets 
£51.80; 15 mg – 10 tablets £18.50. Marketing Authorisation (MA) 
number: EU/1/15/993/001–16. MA holder: Daiichi Sankyo Europe 
GmbH, Zielstattstrasse 48, 81379 Munich, Germany. Date of prep of 
PI: May 2016. EDX/15/0150(2).
Adverse events should be reported. 
Reporting forms and information can be found at 
yellowcard.mhra.gov.uk. Adverse events  
should also be reported to Daiichi Sankyo  
UK Medical Information on 0800 028 5122,  
medinfo@daiichi-sankyo.co.uk
Only LIXIANA® combines:
Proven efﬁcacy comparable to well-controlled warfarin5,6
Superior reduction in clinically relevant bleeding vs. well-controlled warfarin5,6
Once-daily dosing across both NVAF and VTE indications7
NICE RECOMMENDED1,2 AND SMC 
ACCEPTED3,4 IN NVAF AND VTE
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High Scoring Abstracts for Oral 
Presentation
Secondary Prevention
1.  Stroke Prevention Rehabilitation Intervention Trial of Exercise (SPRITE) - A 
Randomised Feasibility Study
Heron N123, Kee F123, Mant J4, Reilly PM5, Donnelly M, Cupples ME123. 
1Dept of General Practice and Primary Care, Queen’s University, Belfast; 2Centre for Public Health 
Research, Queen’s University, Belfast; 3Centre of Excellence for Public Health Research (NI); 4Primary 
Care Unit, Department of Public Health and Primary Care, University of Cambridge, Strangeways 
Research Laboratory, Cambridge, UK; 5Patient and Public Involvement (PPI) representative for SPRITE 
studies.
Introduction: Cardiac rehabilitation post-myocardial infarction is beneﬁcial but its value after a 
transient ischaemic attack (TIA) or minor stroke is untested despite these conditions sharing similar 
pathology. This study’s primary objective was to test the feasibility of conducting a randomized 
controlled trial (RCT) of a novel home-based rehabilitation programme, adapted for patients with a 
TIA/minor stroke.
Method: Patients within 4 weeks of a ﬁrst TIA or minor stroke of atherosclerotic or small vessel disease 
origin were randomly allocated to: (1) standard/usual care; (2) home-based rehabilitation manual or 
(3) manual plus pedometer. Participants received telephone support from a General Practitioner (GP) 
at 1 and 4 weeks, and were invited for re-assessment at 6 weeks. Views regarding the manual and 
study methods were explored in a focus group.
Results: Approximately one quarter (28/107) of clinic attendees (15 men; 13 women) agreed to be 
contacted by the researcher. Our target sample of 15 (10 men, 5 women; mean age 69 years) was 
recruited from clinics in one hospital over an 18-week period and from the 28 eligible patients (54%): 
all completed the study. Group 3 increased pedometer step-counts (mean steps/day 8,356 to 9,763). 
In Groups 2 and 3 sedentary time fell (mean -1.6 hrs, SD -1.52; -1.2 hrs, SD -1.1) and anxiety and 
depression and diet improved. The manual was welcomed, particularly regarding its information 
about stroke signs and symptoms. Pedometers were valued, particularly for goal-setting. Participants 
drew support from others’ experiences and requested that a ‘patient story’ be added to the manual.
Conclusion: Our ﬁndings indicate that a RCT of a novel home-based rehabilitation programme, 
‘The Healthy Brain Rehabilitation Manual’, initiated within 4 weeks of a ﬁrst TIA/minor stroke, and 
with 6-week follow-up is feasible and has potential to improve health. For the next stage in the 
interventions development, the manual’s content will be revised and a patient’s story included.
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Exercise after stroke
2.  Effect of IQoro® training on impaired postural control and oropharyngeal  
motor function in patients with dysphagia after stroke
Hägg M 1, Tibbling L 2 1.Speech and Swallowing Centre, Department of Otorhinolaryngology, Hudiksvall 
Hospital, County Council of Gävleborg, Hudiksvall, Sweden, 1.Centre for Research and Development, 
Uppsala University, Uppsala, Sweden, 2 Department of Otorhinolaryngology, Linköping University, 
Linköping, Sweden.
Introduction: The investigation studied the frequency of Impaired Postural Control (IPC) in patients with 
stroke-related dysphagia, and the effect of IQoro® training on IPC and Oropharyngeal Motor Dysfunction 
(OPMD). IQoro® is a neuromuscular training device requiring 1½ minutes’ training per day.
Method: A prospective clinical study was carried out with 26 adult patients referred by clinicians, with 
stroke-related dysphagia after ﬁrst stroke. The study comprised two groups: the ﬁrst of 15 patients who had 
suffered stroke more than 6 months before, the second group less than one month before. The IQoro® 
training period was 3 months in all cases. Postural control tests and oropharyngeal motor tests were 
performed before training commenced, after the training period, and at a late follow-up (median 59 weeks 
after training).
Results: All patients showed pathological values for all OPM measures at baseline. All parameters 
measured, including OPMD, showed signiﬁcant improvements at completion of IQoro® training: and in 
both groups. Swallowing Capacity Tests showed an average improvement of 6.0ml/sec after training even 
in the late intervention group. 25 of 26 patients exhibited misdirected swallowing at baseline, and only 
two at late follow-up: IPC was not improved in these two individuals either. Five patients were fed via PEG 
at baseline, all were capable of oral feeding after training, and four had their PEGs removed. Timing of 
intervention commencement after stroke was not signiﬁcant in any way.
Conclusion: All patients with dysphagia after stroke have IPC. IQoro® training delivers signiﬁcant and 
enduring improved patient outcomes in treatment of IPC and OPMD.
Service development (research)
3.  Post-Stroke Ankle-Foot Orthoses: Examining Referral Trends in the Scottish  
Multi-DisciplinaryTeam
Morrow EM1, Bowers RJ1 1University of Strathclyde, Glasgow, UK
Introduction: Best Practice Statement: Use of Ankle-Foot Orthoses Following Stroke (BPS) asserts ‘any 
member of the MDT [Multi-Disciplinary Team] can refer a patient for orthotic assessment’; this is supported 
by ISPO Consensus Conference on Stroke. The intention of this study was to 1) assess awareness of the 
BPS 2) assess referral trends for AFOs of the MDT and 3) identify barriers to referral to orthotics in Scotland.
Method: A survey of clinicians was conducted, inclusion criteria being members of the Scottish Stroke 
MDT. An online survey was distributed via Scottish Stroke AHP Forum, Scottish Stroke Nurses Forum, British 
Association of Stroke Physicians and Scottish Stroke MCNs.
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Results: Statistically signiﬁcant association was found between: 
• Awareness of BPS and NHS Board Area; 
• Profession and whether clinicians have previously referred to orthotics;
• Conﬁdence in assessment criteria and profession;
• Referral to departments other than Orthotics and profession.
Nurses, social workers and OTs are unlikely to refer for AFOs; GPs and stroke physicians refer but are 
not conﬁdent in referral criteria; all depend on physiotherapists to assess and refer. The primary barrier to 
referral was a limited ability to deﬁne mobility problems. Physiotherapists identify different barriers: long 
waiting lists and a lack of joint clinics. GPs have a low awareness of the BPS.
Conclusion: Physiotherapists are relied upon by the Stroke MDT to identify mobility problems and refer to 
Orthotics. The BPS should be re-disseminated to identiﬁed groups to improve awareness and conﬁdence in 
referral criteria. Reduced waiting list times and joint clinics may reduce barriers to orthotics.
Acute Care
4. Head Position in Stroke Trial (HeadPoST) results: implications for clinical practice
C. Elizabeth Lightbody, Denise Forshaw and Caroline Watkins, for the HeadPoST Steering Committee, 
Investigators and Coordinators, University of Central Lancashire, Preston, Lancashire
Introduction: Uncertainty has existed over the optimal head position for patients with acute ischaemic 
stroke (AIS) or intracerebral haemorrhage (ICH). Any potential beneﬁts of lying ﬂat in AIS (ie increased 
collateral blood ﬂow) may be offset by increased risks of pneumonia and cardiorespiratory dysfunction, 
whilst sitting up may reduce cerebral oedema in large hemisphere AIS and ICH. The aim of this study was 
to compare the effects of lying ﬂat (0°) with sitting up (?30°) body position in the ﬁrst 24 hours of admission 
for patients with acute stroke on functional outcome, deﬁned by shift in scores on the modiﬁed Rankin scale 
(mRS) at 90 days.
Method: An international, multicentre, prospective, cluster randomized, cross-over clinical trial conducted 
across 114 hospitals in nine countries during 2014-2016. Clusters of a target of 70 consecutively admitted 
stroke patients were positioned to each randomised position according to a standardised protocol as 
policy of usual care to reduce selection bias and contamination. Centralised blinded mRS assessment 
was undertaken at 90 days, reducing observer bias. Sample size calculations were to detect ?16% shift in 
functioning on 90-day mRS using ordinal logistic regression.
Results: 11,094 patients were recruited (mean age 68 yr, 60% male, 91% ischemic). Adherence to each 
randomised head position and follow-up were excellent. There were no signiﬁcant differences in the effects 
on the primary outcome, or serious adverse events including death and pneumonia.
Conclusion: No clear beneﬁts or harms were evident from speciﬁc head positioning in acute stroke.  
These results provide reassurance that head positioning per se is not relevant to stroke outcomes.
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5.  Outcomes after thrombectomy in Belfast: a comparison of drip and ship versus 
mothership paradigms
Adams K1, Burns P2, Hunter A3, Diamond A2, OReilly S2, McKenna B2, Flynn P2, Rennie I2, Smyth G2, 
Kerr E1, Fulton A1, Gordon P1, Patterson C1, Watt M3, Roberts G1, Wiggam MI1Departments of 1Stroke 
Medicine, 2Neuroradiology and 3Neurology, Royal Victoria Hospital Belfast.
Introduction: There is debate as to whether patients with large vessel occlusion (LVO) should be admitted 
to a local hospital followed by transfer for thrombectomy (drip and ship–DS) or routed directly to a 
thrombectomy centre (mothership – MS). Our aim was to compare outcomes of patients who underwent 
thrombectomy in a DS v MS paradigm.
Method: Thrombectomy data was prospectively collected in a single centre serving Northern Ireland 
over a 3 year period. Inclusion criteria were LVO (including basilar), ASPECTS score >5 (if anterior) and 
favourable CT perfusion. The main outcome measure was mRS <3 at 3 months.
Results: 146 patients underwent thrombectomy (DS 59, MS 87). Median NIHSS was similar (DS 15.5, MS 
15.0). The DS group were younger (65 v 71 years, p<0.05). The DS group arrived at the thrombectomy 
centre 230 min after onset, v 91 min in the MS group, p<0.001). Time from arrival to groin puncture 
was shorter in DS (37 v 91 min, p<0.05).  mRS<3 at 3 months was achieved by 59% in DS v 53% in MS 
(p=0.5). The DS group were less likely to achieve full recovery (mRS 0) (9% v 26%, p<0.01).
Conclusion: Functional independence (mRS<3) at 3 months was similar in both groups, but more MS 
patients made a complete recovery. It is likely the DS group represented those with slower ASPECTS 
decay, thus meeting the criteria for thrombectomy despite later presentation at the thrombectomy centre.  
Rapid access to thrombectomy remains essential to optimise both the number of patients treated and the 
outcomes achieved.
Vision
6.  Untreated visual deﬁcits and length of stroke inpatient admissions:  
is there a link?
Wright D1, Donnelly C2, 1Orthoptic Dept, Altnagelvin Area Hospital, 2Orthoptic Dept, South West Acute 
Hospital
Introduction: Since 2008, three sessions per month were offered in Altnagelvin Area Hospital in which 
stroke patients with a suspected visual defect could be assessed and treated. Patients in the South West 
Acute Hospital were seen on an ad hoc basis. According to stats for 2014/15, 19% of stroke survivors 
in Altnagelvin were diagnosed with a new-onset visual defect, while research shows visual defects to be 
present in up to 70% of these patients. Since June 2015, funding from Integrated Care Partnerships has 
provided 7 weekly Orthoptic stroke sessions across the WHSCT. This audit was conducted to determine the 
impact of Orthoptic screening on the rate of detection of visual defects and on the length of hospital stay 
for patients with a visual defect.
Method: Comparisons of case detection; waiting times for assessment; and length of admission were 
made between stroke survivors in 2014/15 (pre-screening) and 2015/16 (screened).
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Results:
• During the ﬁrst 12 months of the service, 311 patients were screened (81% of stroke survivors)                   
•  39% of stroke survivors were found to have a new-onset visual defect (a 105% increase) 
•  36 patients from each group were eligible for analysis of their length of stay. For patients with a new-
onset visual defect, a mean reduction of 3.66 days was found in the screening group compared to the 
non-screened group. This could equate to a trust-wide saving of 514 bed days annually. 
Conclusion: Orthoptic screening of stroke survivors improves the detection rate of visual defects by 105%; 
inﬂuences rehabilitation; and leads to shorter hospital admissions.
Other
7. DOACs: Getting it Right!
Rogers L¹, Healy R², Austin J¹, Connolly D², Crawford E¹, Fearon P¹, Gordon PL¹, Kinnard M¹, O’Donnell 
S¹, Patterson CE¹
¹Acute Stroke Unit, Royal Victoria Hospital Belfast, BHSCT
²Altnagelvin Hospital, WHSCT
Introduction: Prescription of DOACs as a form of anticoagulation has increased signiﬁcantly over last 5 
years. Substantial risk is associated with their use. Careful prescribing is recommended taking into account 
age, weight and renal function. Co-prescribing with other antithrombotics has led to potential and actual 
serious harm for patients. Introduction of education and a checklist aims to improve this. This project was 
carried out in collaboration between the Belfast Health and Social Care Trust and Western Health and 
Social Care Trust.
Method: Retrospective baseline audit of DOAC prescribing over 3 months, followed by implementation of 
several improvement measures (including use of a  bespoke anti-thrombotic page in the regional medicine 
kardex) with continuous data collection during this time. Staff and User feedback collected and analysed.
Results: Baseline safety compliance for DOAC prescribing was 50% in BHSCT Stroke Unit.  
Following several interventions including joint working with the Western Health and Social Care trust, this 
improved to 100%.
Conclusion: Targeted education and use of a checklist improves the safety of DOAC prescribing.  
This is further enhanced by use of a dedicated antithrombotic page in the kardex and should be  
considered regionally.
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Posters
Acute Care
01. A quality improvement project of a stroke thrombolysis pathway
Blythe RJ (1) Orme S (1) (1) Department of stroke medicine, Barnsley Hospital, Barnsley, United Kingdom
Introduction: There is a national recommendation to ensure patients have access to thrombolysis 
and hyper-acute stroke unit (HASU) care for acute stroke. Thrombolysis service was not available 
at Barnsley Hospital due to stafﬁng changes from September 2016. A new thrombolysis pathway 
was developed with collaboration from Barnsley Hospital, local hospitals and Yorkshire Ambulance 
Services (YAS) to ensure ongoing access to thrombolysis for Barnsley patients. Patients identiﬁed with 
acute stroke, suitable for thrombolysis, were assessed and transferred to the nearest thrombolysis 
centre for treatment.
Method: The pathway was developed through local meetings in Barnsley Hospital within the stroke 
team. This was then presented to neighbouring hospitals and YAS. The pathway was agreed and 
actioned. Data was retrospectively collected through repatriated patients’ case note review between 
September-December 2016.
Results: A total of 27 Barnsley patients were transferred to 4 neighbouring hospitals for assessment 
between September-December 2016. 5 patients underwent thrombolysis. Mean time of symptom 
onset to arrival at neighbouring centre was 1hr 42mins. Patients were repatriated with a mean time 
of 5hrs 40mins. Transfer of patient documentation was generally low. Between August 2015-August 
2016 average thrombolysis rates were 3.25 per month. Since the pathway was introduced between 
September-December 2016 the thrombolysis rate has reduced to 1.3 per month.
Conclusion: There are plans for thrombolysis and HASU care within South Yorkshire to go through 
signiﬁcant change in the near future. Ongoing quality improvement of the repatriation pathway 
including communication, effective hand-over of patients and appropriate and timely thrombolysis is 
crucial to maintaining patient safety and standards.
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02. SWALLOW SCREENING - Does pneumonia incidence improve?
Marco Silingardi Acute Stroke Unit, Salford Royal Hospital, Stott Lane, Salford – M6 8HD
Introduction: Dysphagia after stroke is related to a high risk of aspiration, pneumonia, disability 
and death. Swallowing screening aims to identify individuals that may have dysphagia and require a 
specialist assessment. Consensus about the procedure remains strong in practice although there is no 
robust supporting data.
Method: Articles in English (<5 years) were searched in several databases using: <<stroke OR 
“cerebrovascular accident” AND dysphagia OR swallow AND screening OR evaluation AND 
pneumonia OR chest infection>>. Only 3 articles met the inclusion criteria.
Results: Sorensen (2013) reported pneumonia in 7% (96.5% SS performed) and 28% (58.3% SS 
performed). Masrur (2013) found patients with HAP had a higher initial NIHSS score (10 vs 4), 
swallow screening performed more often (75.5% vs 68.5% - OR 1.1) and increased mortality (12.4% 
vs 2.3%). Bray (2016) found increased incidence of HAP (13.8% vs 8%) and 30-day mortality (34.6% 
vs 10.2%) in the group where no swallow screening was performed. Patients in the fourth quartile  
(> 344 minutes) had higher risk to develop SAP (OR 1.33). Considering NIHSS in the analysis 
showed risk of 36% (aOR 1.36). An association was found between delays in screening and incidence 
of HAP.
Conclusion: The relationship between swallow screening and HAP in Masrur (2013) is biased by the 
high rate of missing data and swallow screen not performed. Sorensen (2013) found incidence 21% 
higher (28% vs 7%) in the control group but methods limitations should be considered.  
Bray (2016) found an association between delays in screening and HAP. These ﬁndings support the 
stroke guidelines despite further studies are needed.
Assistive Technology
03.   A review of assistive technologies - exploring the effects on upper limb  
function with conventional therapy and the feasibility of their implementation
Spencer HJ University Hospital of South Manchester, U.K.  Faculity of Health, Psychology and Social 
Care, Manchester Metropolitan University, U.K.
Introduction: The nice guidelines 2010 state that patients should receive 45 minutes of each relevant 
therapy 5 days a week. Finical pressures and limited budgets, with a reduced number of therapists 
and an increasing number of more dependent patients makes this challenging, if not impossible, on 
a day to day basis. Assistive technologies could enable patients to engage in a variety of therapies 
independently or whilst supervised by an assistant, freeing up clinical time for qualiﬁed therapist to 
continue with complex treatments or assessments. This study will compare neuromuscular stimulation, 
virtual reality and robotic technology with conventional therapy.
Method: MMU database used to perform a search from 2012 to present using the key words 
“neuromuscular stimulation” or “virtual reality” or “robotics” with “acute stroke” and “upper limb 
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function”. Studies were excluded if the technology was not used in acute stroke rehabilitation, if a 
very small sample size was used, less reliable outcome tools were used or the technology was used in 
conjunction with another treatment modality.
Results: No signiﬁcant differences were found between the assistive technologies and conventional 
therapy. All technologies demonstrated an improvement in function, using the Action Research Arm 
Tool (ARAT), pinch and grip strength and Fugl-Meyer assessment (FM), over time.
Conclusion: Cochrane reviews demonstrate that there is only low to moderate quality evidence into 
assistive technologies. Further research is required into this area prior to a change in guidelines. 
However, patients enjoyed the variety within their rehabilitation; money could be saved long term and 
therapists time could be used more efﬁciently.
Case reports and interesting cases
04. Bi-Thalamic and Mid-brain Infarct: Artery of Percheron (AOP) Syndrome
1. Hassan. MS, 2.Stoppard E, 3. Albazy L, 4. Gaba W. 
Department of Stroke Medicine Airedale General Hospital and Bradford Teaching Hospital, West 
Yorkshire, UK.
Introduction: The thalami and midbrain share a complex blood supply. Occlusion of Artery of 
Percheron (AOP), a rare anatomic variant, in which a single arterial trunk arises from Posterior 
Cerebral Artery, causes a bilateral para-median thalamic infarct with or without rostral mid-brain 
infarct. AOP stroke is characterized by three cardinal features of vertical gaze palsy, memory 
impairment and coma. AOP infarction accounts for 0.1% to 0.3% of all ischemic strokes of which up 
to one third are associated with thalamic infarction.
Case report - A 49-year-old lady with background history of diabetes mellitus type 2, hypertension 
and dyslipidaemia was admitted after collapse at home. On examination she was tachycardic and 
hypertensive. Her Glasgow Coma Scale (GCS) was 7 with ﬂuctuating conscious level. Her speech 
was slurred and hypophonic. She had a complete right sided ptosis; dilated and ﬁxed right pupil, 
vertical gaze palsy and, right facial palsy. She was also quadriperetic. CT scan of head was normal. 
IV thrombolytic therapy was given. Echocardiogram, ECG, and seven day Holter monitoring were 
all normal. Stroke in young workup including complete vasculitis and thrombophilia screen were 
negative. Repeat CT brain next day showed acute bilateral para-median thalamic and mid-brain 
hypodensity. However, CT Angiogram of head and neck was unremarkable. She is making good 
progress with ongoing rehab in stroke unit.
Discussion: Thalamus has a variable blood supply which overlaps with midbrain. Clinical signs and 
comprehensive radiological imaging helps diagnosing AOP infarct. AOP is not always easily seen in 
conventional angiographic imaging as this vessel is very minute.
References:
1.  Teoh HL, Ahmad A, Yeo LL, Hsu E, Chan BP, Sharma VK: Bilateral thalamic infarctions due to 
occlusion of artery of Percheron. J Neurol Sci. 2010 Jun 15; 293(1-2):110-1.
2.  Raphaeli G, Liberman A, Gomori J, Steiner I: Acute bilateral paramedian thalamic infarcts after 
occlusion of the artery of Percheron. Neurology 2006, 66:7.
3.  Shea YF, Lin OY, Chang RSK, Luk JKH. Artery of Percheron infarction. Hong Kong Med J. 
2012;18:446. e1–2. [PubMed]
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05. A Run too FAST
Adams K ¹, Gordon PL ¹, Acute Stroke Unit, Royal Victoria Hospital, Belfast Health and Social Care Trust 
We describe the case of a 26 year old with no signiﬁcant past medical history who attended the 
emergency department following a collapse at the ﬁnish line of a half marathon.
Investigations identiﬁed acute kidney injury, rhabdomyolysis,  deranged liver function tests with a mildly 
elevated bilirubin and signiﬁcant transaminitis. Platelets were normal however fell to 98 on day 3 
before gradually returning to normal over the following days. Coagulation screen revealed a slightly 
elevated prothrombin time of 13.50 but was otherwise unremarkable.
The patient’s cognition improved but he continued he had no recollection of events surrounding the 
race. An MRI showed small areas of acute infarction in both cerebellar hemispheres. CT angiogram 
revealed a right sided aortic arch with no other abnormalities. An echocardiogram conﬁrmed the 
previously undiagnosed dextrocardia with situs inversus, however, the heart was structurally normal 
with no evidence of an intra-cardiac shunt. 24 hour ECG showed no evidence of arrhythmia.
Initial working diagnosis was that of a hypoperfusion injury or embolic shower of uncertain cause and 
antiplatelet therapy was initiated. In light of the transient thrombocytopenia a haematology opinion 
was sought.  
Findings were consistent with haemolysis, with features of muscle breakdown. He was diagnosed 
with March Haemoglobinuria, a direct consequence of running the half marathon which is caused 
by red cell intravascular haemolysis. Haemolysis causes vasoconstriction due to the effect of plasma 
haemoglobin, which is the likely cause of his cerebellar infarcts, acute kidney and liver injury.  
Further blood tests excluded other haemolytic disorders.
06.  A case of pontine infarct demonstrating the importance of eye position on 
      CT imaging
CA Ashmore1, CT Mansbridge1, N Smyth1
1Hyperacute Stroke Unit, Royal Hampshire County Hospital, Winchester, UK
Introduction: Eye position, which may be seen on CT imaging, has previously been documented as 
an important sign of early middle cerebral artery ischaemia. Pontine infarcts may also present with 
abnormalities of eye position, diagnosis of which may be aided by eye position on CT imaging.
Method: A 74 year old gentleman presented to the emergency department with sudden onset 
diplopia while walking his dog. He had a history of previous spontaneous pulmonary embolisms,  
for which he was anticoagulated with warfarin (INR 2.5). On examination there was lateral deviation 
of his right eye and he was unable abduct or adduct his left eye, in keeping with one-and-a-half 
syndrome.
Results: Initial CT of the brain was unremarkable; however, lateral deviation of the right eye was seen 
on the images. This was consistent with a paralytic pontine exotropia. T2 and diffusion-weighted MRI 
later showed a high signal in the posterior pons to the left of the midline, conﬁrming the suspected 
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diagnosis of a left paramedian pontine infarct. He was managed with anti-platelet therapy and 
secondary prevention.
Conclusion: Our case further highlights the importance of eye position in the diagnosis of acute 
stroke. The initial CT scan was normal, other than a right exotropia, which proved to be an important 
clue to the diagnosis of a pontine infarct, later seen on MRI.
07. Is there a link between Migraine and Bell’s palsy?
M. S. Hassan, W. H. Gaba, Department of Stroke Airedale General Hospital & Bradford Teaching 
Hospital, Bradford, U.K.
Introduction: Migraine is quite common, with an annual global prevalence of about 10%.  
Research suggests that patients with migraine have almost double the risk of developing Bell’s palsy. 
We present a patient who was referred to us as an Acute Stroke.
Method: Case Report: 32 years old male presented with sudden slurred speech, right face, arm 
and leg weakness with no associated headache. Past medical history includes hypertension, hyper-
lipidemia and migraine. He was current smoker with 15 pack years. He denies any alcohol or illicit 
drug. On examination he was normotensive, and had expressive dysphasia, right LMN facial palsy, 
right arm pronator drift and right leg drift. NIHSS was 6. CT brain was normal. ECG showed sinus 
rhythm. He was offered thrombolysis but he refused and self-discharged. Next day he was seen in TIA 
clinic where he reported worsening of his symptoms and was admitted to Stroke Unit. Extensive stroke 
workup including MRI & MRA brain, Echocardiogram, 24 hour ECG, Carotid Doppler, Vasculitis & 
Thrombophilia Screen was normal.
He made good recovery and was discharged home with follow-up in six weeks when he described 
recurrent headaches with visual aura. Symptoms were relieved by Sumatriptan. He had no focal 
neurology except residual right LMN facial palsy. His repeat MRI Brain was normal. He was seen by 
our Neurologist and we made a ﬁnal diagnosis of Hemiplegic Migraine with Bell’s palsy.
Results: Discussion: Bell’s palsy and migraine might share a common pathogenesis. Further research 
is needed to establish this causal relationship.
Conclusion: References: 
1. Migraine May Double Bell Palsy Risk By Mark L. Fuerst January 13, 2015 
2. Migraine Linked to Risk for Bell’s Palsy. Pauline Anderson. Medscape. Dec 18, 2014.
3.  Increased risk of Bell palsy in patients with migraine. A nationwide cohort study. Neurology January 
13, 2015 vol. 84 no. 2 116-124 
      Kuan-Po Peng, MD*, Yung-Tai Chen, MD*, Jong-Ling Fuh, MD, Chao-Hsiun Tang, PhD and  
Shuu-Jiun Wang, MD
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08.  Pyroglutamic acidosis: a rare stroke mimic
Mac Lochlainn DJ1, Hamilton P2, Wiggam I1, 1Acute Stroke Unit, Royal Victoria Hospital, 
2Clinical Biochemistry Department, Royal Victoria Hospital
Introduction: Many conditions can mimic acute stroke. Accurate diagnosis is important, as some 
require urgent management. Pyroglutamic acidosis is an under-diagnosed cause of a high anion gap 
metabolic acidosis (HAGMA), which has been reported to present with acute neurological features.
Method: We reviewed the case of a patient who presented to the Royal Victoria Hospital.
Results: A 67-year-old female with a background of bipolar disorder, type 2 diabetes mellitus, 
hypertension, and chronic kidney disease presented as a stroke lysis call with dysphasia, dysarthria, 
and facial droop. The patient was outside the time window for thrombolysis. No acute abnormality 
was detected on CT brain, CT angiography, or MRI brain. The patient was subsequently diagnosed 
with a multi-factorial acute kidney injury, E. coli urosepsis, lithium toxicity, and a HAGMA. Serum 
lactate and ketone levels were normal. The patient’s renal function and inﬂammatory markers 
improved with appropriate management; however, the HAGMA persisted. Specialist advice was 
sought. Elevated levels of pyroglutamic acid were detected in a urinary organic acid proﬁle. 
Paracetamol and antibiotics were discontinued, and oral sodium bicarbonate was initiated.  
At discharge, both the HAGMA and neurological symptoms completely resolved.
Conclusion: Pyroglutamic acidosis is a rare stroke mimic. It is associated with drugs including 
paracetamol, ﬂucloxacillin, and alcohol, malnutrition, pregnancy, renal failure, liver failure, female 
gender, and sepsis. Withdrawal of causative agents is the mainstay of treatment, although sodium 
bicarbonate and N-acetylcysteine are sometimes used. Early clinical diagnosis is important as results 
may take several days and laboratory testing is not widely available.
Other
09.  An Investigation of the Challenges that Therapists Perceive in Rehabilitation  
of Upper Limb Following Stroke
1Kontzoglou A, 2Snowdon  N 1Department of Allied Health Professions, Shefﬁeld Hallam University, 
UK, 2 Department of Allied Health Professions, Shefﬁeld Hallam University, UK
Introduction: Upper limb (UL) rehabilitation following stroke has low success rates that ﬂuctuate 
between 15% and 20%. Understanding the challenges that therapists face with post- stroke UL 
rehabilitation could enable application of appropriate interventions and a better allocation of 
resources.
Method: Data was gathered from an open question answered by 87 therapists, in an open 
online course, delivered by Shefﬁeld Hallam University (SHU) in June 2016. Participants included 
physiotherapists and occupational therapists from a wide range of countries. They were asked to 
explain the challenges they face in post- stroke UL rehabilitation. The project was approved by SHU 
Faculty of Health and Wellbeing Research Ethics Committee and no course participants asked to have 
their comments withdrawn. Thematic analysis was conducted and participants categorized according 
to their key challenges, to explore any differences between countries or professions.
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Results: The feeling of uncertainty suggests that therapists felt daunted by the severity and complexity 
of stroke, the range of assessment and treatment options, the lack of a deﬁned professional 
role in rehabilitation, and unclear evidence. The lack of knowledge and skills included difﬁculty 
communicating with stroke survivors, particularly the more severely affected, and a lack of experience 
in helping stroke survivors to exercise independently of the therapist.
Conclusion: These ﬁndings suggest a need for training focused on achieving a research-informed, 
whole- person approach to rehabilitation, along with the communication skills required to negotiate 
goals and rehabilitation plans with stroke survivors. Guidelines could be developed to assist clinicians 
in prioritizing rehabilitation aims.
10.   ‘Lunch Club’ - a therapy-led service improvement promoting multi-faceted  
stroke rehabilitation
Godsall R (OT), Walkden J (physio), Hewitt E & Olczak C (SLTs), Mudd P(Dr) - Royal Devon and Exeter 
Hospital NHS Foundation Trust
Introduction: Attending a communal space for lunch could serve rehabilitative functions.  
Our concept was to create a normalised setting, detached from the ward environment, in which to 
supplement and consolidate individual therapeutic management. The multidisciplinary team discussed 
how patients might beneﬁt in terms of their mobility, communication, swallowing, mood and social skills. 
The RCP guidelines for Stroke (2016) advocate activities that increase social participation.
Method: Our 28 bed ward cares for hyperacute & acute stroke patients and those continuing 
rehabilitation until a suitable community hospital or therapy team is available. Patients are considered for 
Lunch Club if they show interest and are likely to beneﬁt from the full 60 minute session.  
Patients may sit unsupported or use a supportive wheelchair or tilt in space chair. Normal and modiﬁed 
diets are acceptable. Patients requiring support for ﬁne or gross upper limb movement are supported 
by therapy staff and appropriate equipment. Patients with aphasia are supported by trained staff and 
with communication strategies. We encourage patients to wear their own clothing to further normalise 
the environment. Patients with cognitive problems are not excluded - however, some patients may ﬁnd 
a stimulating, busy environment distracting, making it unsuitable therapeutically - this is considered on 
an individual basis. Patients with continence problems are supported with appropriate aids. There are 
no limits with respect to age or gender, but staff are sensitive to offer patients companions likely to have 
similar interests and functional abilities. Patients receive a verbal description of Lunch Club before verbal 
consent is obtained. Patients are encouraged to walk 10-20m to and from the lunch room with a therapist 
and appropriate facilitation/aids. Patients engage in social interaction/conversation with other patients, 
therapists and healthcare assistants seated at the tables. Patients are observed (and assisted) by therapists 
with regards to cutlery use, spatial awareness and swallow safety.
Results: Patients can be observed functioning in a normalised environment e.g. regarding their listening 
skills and understanding, turn taking and the ability to initiate conversation. The MDT can assist patients 
with supported communication strategies, as identiﬁed in individual therapy sessions.
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As well as increasing social participation, Lunch Club enables dysphagia management and allows Speech 
Therapists to assess several patients over the course of a meal when patients are seated at the same 
table. This has been time-efﬁcient for patients requiring upgrades of modiﬁed diet or if a meal assessment 
would be more beneﬁcial in order to further objectify dietary consistency recommendations. We also ﬁnd 
Lunch Club useful in implementing dysphagia management strategies, such as modifying bolus size and 
considering pacing.
Patients typically receive about 60 minutes of therapy at Lunch Club. Each month about 35 stroke patients 
attend. Therapist input involves 4 qualiﬁed staff and 2 assistants for each Lunch Club – this is under review 
to ensure that stafﬁng levels on the ward remain equitable for all patients during this period. 
Our SSNAP team centred data improved to a score ‘B’ for Speech and Language Therapy.
Patient centred SSNAP score for SLT improved to ‘C’, having previously been ‘E’.
Conclusion: Lunch club has favourable reports from patients and staff; it allows various forms of 
individualised therapy in a communal area and has beneﬁts in terms of socialisation and mood; it helps 
staff deliver targeted therapy in a time-efﬁcient manner.
Secondary Prevention
11. Deep Venous Thrombosis (DVT) after stroke. Effective Prophylactic measures
Abathar A. School of Medicine, Keele University / UK
Introduction: Treatment of Deep Venous Thrombosis (DVT) is sufﬁcient in preventing morbidity and 
mortality after stroke. However, fatal Pulmonary Embolism (PE) caused by a symptomless DVT is the 
cause of 25% of the early death. Current practice should be proactive rather than reactive with clinical 
staff stratifying risk on admission and implementing appropriate methods of management and reviews 
rather than waiting for symptoms to appear. The risk stratiﬁcation of DVT is completed as standard at 
assessment to the Acute service at that point of time. The identiﬁed incidences of DVT / PE’s, however, 
occurred following this within the ﬁrst two weeks and diagnosed when symptomatic once transferred 
to another unit. The national guidance updated recommends the use of IPC for up to 30 days for 
identiﬁed patients.
Method: The stroke unit in County hospital patient’s record was explored from January-December 
for 2015 and from Jan-Dec 2016 looking for the incidence of the in-hospital DVT and PE 220 stroke 
patients admitted to the ward during 2015. Lower limb DVT diagnosed in 4 and PE in 2. While in 
2016, another 200 patients were admitted, and only 2 patients developed DVT.
Results: 220 stroke patients admitted to the ward during 2015. Lower limb DVT diagnosed in 4 and 
PE in 2. While in 2016, another 200 patients were admitted, and only 2 patients developed DVT.
Conclusion: Post-stroke DVT has a massive burden on the patient’s life. However, it could be easily 
tackled by imposing evidence-based prophylactic measures like IPC. This could be seen clearly 
improve the ward practice when the incidence of DVT reduced by tow-third in 2016 after successful 
implementation of IPC in all ward’s bed. Also, alerting the medical staff about the urgency of the 
diagnosis and treatment of DVT/PE through programmed workshop inside the hospital.
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Ongoing Trials
Education and Training
OG1.  Promoting integrated team working across the Stroke Care Pathway -  
The South Dublin Allied Health Professionals Stroke Forum (SDSF)
O’Reilly F, McCaffrey A. The Royal Hospital Donnybrook on behalf of the South Dublin AHP Stroke 
Forum
Introduction: The SDSF was established in 2010 by three allied health professional (AHP) teams 
working across the continuum of stroke care: acute, rehab and community. The aim of this group was 
to enhance communication and peer support among services and facilitate a smooth transition of 
patient care along the stroke pathway.
Method: Held on a four-monthly basis, this forum has examined a diverse range of subjects.  
Core objectives include inter-hospital networking, promotion of continuing professional development 
(CPD) through expert presentations, literature reviews, and development of service initiatives. A survey 
of members was conducted to identify the value of this forum and to determine areas for future 
consideration.
Results: All respondents found the forum beneﬁcial to their practice. Members felt strongly that it 
contributed to interdisciplinary working, CPD, and the implementation of local service developments.  
Outcomes include: compiling a directory of stroke AHPs in South Dublin, implementing improved 
Stroke driving screening, provision of patient information on Sexuality and Stroke, Introducing 
the Oxford Cognitive Screen into practice, FIM+FAM training and development of an upper limb 
programme. This group has expanded over the years to include members from six stroke services.  
Future objectives include developing a community based young adult stroke support group, promoting 
a public awareness initiative, and conducting cross site research.
Conclusion: The information presented suggests that allocating time to cross site working and 
pooling of knowledge and skills can contribute to developing evidence based initiatives that could 
help enhance the quality of care for the stroke survivor and their relatives.
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OG2.  Meeting the Need for Shared Learning in the Delivery of Integrated  
Stroke Rehabilitation – Establishing and Implementing an Interdisciplinary  
‘Stroke Skills Workshop’
O’Reilly F, McCaffrey A. On behalf of the Stroke Rehabilitation Team. The Royal Hospital Donnybrook, 
Dublin. Ireland.
Introduction: In an effort to support upskilling and integration of new ward based staff into a stroke 
rehabilitation team and to meet the recommendations that ‘all people working with stroke patients  
are trained in Stroke Core Competencies’ (HSE 2017), a Stroke Skills workshop was devised and 
rolled out.
Method: A three-module programme was developed for rehabilitation staff. It included an accredited 
online module; the Stroke Training and Awareness Resources (STARS) and two modules of an 
interdisciplinary education workshop with a large practical component covering 20 Stroke Core 
Competencies. An evaluation form was completed by staff to direct future development.
Results: Of 18 respondents, the majority of staff trained were health care assistants and nursing staff.  
All staff rated the training quality as either excellent or very good and they felt it would beneﬁt their 
clinical practice. One hundred per cent of staff felt it would promote closer working. Open question 
responses were strongly positive. Areas of beneﬁt included; practical demonstrations, training on 
postural management, handling techniques and discussion around case examples to illustrate  
‘points that everyone could relate to’. Use and rationale for equipment such as dressing aids, splints 
and orthoses. Suggestions for future training were proposed.
Conclusion: This blended model of: e-learning, taught core competencies, and an interactive 
practical workshop was positively received by all staff. In particular, the emphasis on practical skills 
and the 24-hour approach to rehabilitation has contributed to enhanced interdisciplinary working in 
the service.
Rehabilitation
OG3. Fluoxetine or control under supervision (FOCUS)
C Williams, for the FOCUS Trial Collaborators Centre for Clinical Brain Sciences, University of 
Edinburgh, Edinburgh, United Kingdom 
Introduction: Recent small trials suggest that selective serotonin reuptake inhibitors improve 
neurological and overall recovery after stroke. Our aims are to determine whether ﬂuoxetine 20mg 
daily for 6 months, started at 2-15 days after stroke onset in patients with persisting neurological 
deﬁcits, reduces dependency at 6 months and whether any beneﬁts persist to 12 months
Method: This UK wide, multicentre, randomised placebo-controlled trial aims to recruit more than 
3000 patients. Eligible patients providing informed consent are randomised by a central web-based 
system. Patients’ progress in-hospital and early adherence are collected by local follow-up at hospital 
discharge (for inpatients) and central follow-up at one month (for outpatients). 
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Other secondary outcomes (survival, health related quality of life, mood, fatigue, Stroke Impact 
Scale), new clinical diagnosis of depression and resource use) are collected at 6 and 12 months via 
postal, or telephone questionnaires to patients and general practitioners. Based on a sample size for a 
binary outcome, a trial of 3000 (1500 per group) will provide greater than 90% power  
(alpha = 0.05) to detect a 5.5% absolute increase in proportion of patients with a modiﬁed Rankin 
score of 0-2 (i.e. independent) (odds ratio = 1.30). We have harmonised assessments with the 
Australian AFFINITY (Assessment of ﬂuoxetine in stroke recovery) and Swedish EFFECTS (Efﬁcacy oF 
Fluoxetine – a randomisEd Controlled Trial in Stroke) trial We have harmonised assessments with the 
Australian AFFINITY (Assessment of ﬂuoxetine in stroke recovery) and Swedish EFFECTS (Efﬁcacy oF 
Fluoxetine – a randomisEd Controlled Trial in Stroke) trial.
Results: Recruitment closed 31st March with more than 3000 patients.
Conclusion: FOCUS will tell us whether ﬂuoxetine, improves overall recovery in a broad range of 
stroke patients.
OG4.  Using apps for rehab
Ruth Siewruk - Northern Devon HealthCare Trust
Introduction: Project to explore use of apps for rehab within stroke. 5 year project testing different 
apps and creating a free, impartial on-line resource. www.my-therappy.co.uk
Method: An interactive workshop to cover the following: - 
• Introduce the concept of using “Apps” as a rehab tool. 
•  Demonstrate how Apps can be used in a clinical session (videos of actual patients using, mock 
treatment sessions and case studies in groups as an interactive discussion practical session). By 
the end participants would hopefully have an idea of the practical application of Apps in a clinical 
setting and have the skills to start to implement this in their own practice,
•  Demonstrate a variety of Apps that are suitable for use helping to rehab post stroke to cover 
cognition, upper limb, vision, mood, function, exercise tolerance, speech and much more (we can 
provide a variety of iPads and Android tablets with tried and tested Apps on for people to trial and 
practice on during the session), 
•  Introduce the Northern Devon Healthcare NHS Trust App review website which is due to go live in 
summer 2015 and will be freely available for clinicians and patients, 
•  Provide information on where to get recommended apps from. The session would consist of a 
few minutes introduction in a presentation style, followed by breaking into groups to use, try and 
clinically reason the use of Apps with case studies and practical examples, everyone back together 
for feedback, closure presentation to introduce how to ﬁnd ideas of what Apps are suitable.
Results: Previously presented at UKSF 2014 (brag and steal) and 2015 (workshop). We have been 
using Apps successfully for a number of years and have reﬁned how to identify, critique, use and 
review apps including having an app pathway. Our website been nationally recognised and is being 
recommended by the Life After Stroke Centre and Headway. It has also just been shortlisted for an 
advancing health care award.
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0G5.  A pilot randomized control trial (RCT) of mirror box therapy in upper limb 
rehabilitation with sub-acute stroke patients
Alison Porter-Armstrong¹, Patricia McIlwaine², Lourene Abbi², Nicola Gallagher¹, Ian Bradbury¹, May 
Stinson¹, ¹School of Health Sciences, University of Ulster, Northern Ireland, ²Occupational Therapy 
Department, Northern Health and Social Care Trust, Whiteabbey Hospital, UK
Introduction: Individuals who have sustained a stroke are often left with residual deﬁcits of the upper 
limb that can restrict functional use of the limb in everyday activities and can result in dependency 
upon others to engage in some tasks. Regaining independence through functional use of the arm and 
hand is the aim of occupational therapy (OT) interventions. Mirror box therapy (MBT) is a relatively 
new innovation being introduced into OT. Some studies have reported it to be beneﬁcial in upper limb 
rehabilitation, and this pilot study aims to provide evidence, using RCT design, as to whether this type 
of therapy may offer greater potential in functional gains in the sub-acute recovery period of stroke 
than standard rehabilitation of the upper limb alone.
Method: 50 participants, meeting inclusion criteria, will be randomized into two groups (treatment 
n=25; control n=25). Participants in both groups will receive standard OT assessment and treatment 
for upper limb rehabilitation throughout their in-patient stay. Participants in the treatment group will 
additionally undertake two 20-minute sessions of MBT, ﬁve days/week. Outcome measures will be 
completed by an independent assessor every 2 weeks up until discharge and at 3/6 months post-
discharge. Outcomes include the Wolf Motor Function Test; the Functional Independence Measure; 
the Canadian Occupational Performance Measure and the EQ-5D-5L.
Results: This 3-year study commenced in March 2015. This presentation will explore the use of MBT 
in upper limb rehabilitation, outline the protocol for the study and comment upon the early stages of 
implementation.
Conclusion: This is an ongoing study due to ﬁnish in January 2018.
OG6.  Study of the Impact of Occupational Therapy Task Speciﬁc Training on  
Upper Limb Function and Quality of Life
Simms L, Cannon J, Department of Occupational Therapy, The Royal Hospital Donnybrook, Dublin, 
Ireland
Introduction: Task Speciﬁc Training (TST) is deﬁned as training or therapy where patients practice 
context-speciﬁc motor tasks whilst receiving feedback. TST focuses on improving occupational 
performance in functional tasks through goal-directed practice and repetition. A TST programme was 
established in The Royal Hospital Donnybrook (RHD) to assess the impact on upper limb functional 
outcomes and on patient’s quality of life. The feasibility of implementing a TST Programme on an 
ongoing basis in terms of resources, time, and patient motivation/engagement was also evaluated.
Method: A prospective, observational study is underway using a convenience sample of in-patients 
in the RHD. A 6 week treatment programme was set up which involves 2 x individual therapy sessions 
and 2 x group sessions per week. The sessions involve timing participants as they complete 3 
repetitions of 3 personalised tasks for 1 minute per rep.
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Results: We have results on 11 patients (expected N=15 by June 2017).
Data for mean scores for more-affected hand analysed using Paired t test 
Dynamometer - 33% improvement; P=0.0358 ie, statistically signiﬁcant.
Box & Block - 21% improvement; P=0.2323 ie, not statistically signiﬁcant.
Wolf - 27% improvement; P=0.0005 ie, extremely statistically signiﬁcant.
Neuro-QoL - 3% improvement; P=0.0017 ie, very statistically signiﬁcant.
9 Hole Peg Test - 64% of patients could complete this initially. 
100% completed this test by programme end.
Conclusion: All outcome measures have shown improvement in patient’s performance. Three out of 
six outcome measures demonstrate statistically signiﬁcant improvements.
OG7. Talking about sex after stroke - what, when and how
Stevens J CLAHRC Greater Manchester, University of Manchester
Introduction: The RCP guidelines found sexual function and activity after stroke is a topic often 
overlooked by healthcare professionals and unlikely to be broached by stroke survivors without 
prompting (RCP, 2016). Evidence in this area often relates to medical intervention, but what other 
evidence for intervention is there?
Method: A literature review was undertaken using the CINAHL database, and papers reviewed.  
An advisory group of stroke survivors and carers was also convened to assist with steering the actions 
following the ﬁndings of the review.
Results: Most research to date has looked at healthcare professionals’ attitude and barriers to 
providing advice about sexual relationships after stroke. There is scant evidence of what stroke 
survivors want to be told, when and how. In addition much emphasis is placed on medical and 
psychological intervention. Stroke survivors say that it is also important to look at practical (positioning) 
communication, and continence issues and that sex after stroke should have an MDT focus.
Conclusion: The next steps will be to work with the advisory group to establish an assessment tool 
which is acceptable to them, and resources to enable an MDT approach. Evaluation of this will follow, 
in the hope that the next guideline will be able to inform more widely on sex after stroke.
OG8. CLCH Stroke Peer Mentoring Scheme
Eleanor Levi, Central London Community Health care
Introduction: A local stroke focus group was held in 2011, which consisted of local stroke survivors, 
carers and local professionals. It was agreed that there was a need for low level emotional support 
from people who really understood what it was like to live life following a stroke. There was a 
discussion about gaps in local services and the need for a range of longer term community based 
services to support stroke survivors. CLCH community neuro rehab team were commissioned to set up 
the peer mentoring scheme in Kensington & Chelsea borough.
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Method: Peer mentoring consists of one to one ﬂexible sessions either in a mentees home or in 
the local community. The scheme provides sharing of experience, help with the recovery process. 
Motivating people to regain conﬁdence. Mentors become volunteers and are provided with training, 
Support and supervision and a contribution to their travel expenses. All mentors are DBS checked.  
This scheme not only provides support for those needing it but enables mentors to feel empowered by 
helping others.
Results: As a result of this scheme, mentees have become mentors and go on to support others, they 
are able to regain conﬁdence and come to an acceptance of their situation and are  able to look 
forward as opposed to mourning a past life due to the effects of stroke.
Conclusion: The Scheme is on-going and we plan to be able to provide this scheme in other 
boroughs, and continue to empower stroke survivors. We are currently continuously recruiting 
members for both roles.
Secondary Prevention
OG9. REstart or STop Antithrombotics Randomised Trial (RESTART)
C Williams, for the RESTART trial collaborators.
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
Introduction: For adults surviving stroke due to spontaneous (non-traumatic) intracerebral 
haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the 
prevention of vaso-occlusive disease before the ICH, does a policy of starting antiplatelet drugs result 
in a beneﬁcial net reduction of all serious vascular events over at least six months compared with a 
policy of avoiding antiplatelet drugs? Do brain microbleeds modify the effects of antiplatelet drugs? 
Participants: Adults surviving ICH who had taken an antithrombotic drug for the prevention of vaso-
occlusive disease before the ICH.
Method: Intervention: Start antiplatelet drugs (aspirin, clopidogrel or dipyridamole; chosen at 
investigator’s discretion). Optional sub-study of brain magnetic resonance imaging (MRI) to assess 
microbleeds before randomisation. Comparator: Avoid antiplatelet drugs.
Outcomes: recurrent symptomatic ICH (primary); vaso-occlusive events, symptomatic stroke of 
uncertain type, other fatal events, modiﬁed Rankin Scale score, and adherence to antiplatelet drugs 
(secondary).
Randomisation: Central, web-based system using a minimisation algorithm, with 1:1 treatment 
allocation to which central research staff are masked.
Results: Follow-up: Central: annual postal or telephone questionnaires to participants and their GPs. 
Local: medical records and any brain imaging relating to outcomes. Administrative data:  
Death certiﬁcates and Hospital Episode Statistics. Sample size: At least 720 participants in the main 
trial (at least 550 in the MRI sub-study). 385 participants have been recruited by 14th March 2017.
Conclusion: Recruitment: Ongoing, closing 31 May 2018. Registration: ISRCTN71907627.  
Website: www.RESTARTtrial.org
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OG10.  Improving Screening for Sleep Apnoea with a Valid Clinical Screening Tool - 
Through Quality Improvement (QI) Methodology
Keegan BC, Sin J, McGartland L, Jordan C, Grimes S.South West Acute Hospital, Enniskillen, UK.
Introduction: People with sleep apnoea are at increased risk of cerebrovascular events.  
Accordingly, the Royal College of Physicians has recommended screening with a validated clinical 
screening tool, and onward referral of those screening positive. We aimed to implement these 
guidelines and have utilised QI methodology to do so.
Method: Starting at a routine screening level of 0% upon our stroke unit, we set about introducing the 
STOPBANG questionnaire as a validated screening tool; in order that we might identify appropriate 
individuals for potential risk factor modiﬁcation. Left to consideration upon ward rounds, screening 
levels remained poor. Securing Junior Doctor buy-in to the project enhanced screening rates, albeit 
to levels below intended target. Review of QI progress with introduction of STOPBANG into Stroke 
Patient clerking proformas, increasing awareness of sleep apnoea with posters upon the stroke unit, 
and most recently delivering of formal teaching at stroke unit multidisciplinary education session has 
facilitated improvement in screening.
Results: At baseline, there was no routine screening of patients for sleep apnoea as a stroke risk 
factor upon our stroke unit. Since introduction of our QI programme, screening rates have increased 
from 14% to 66%, with identiﬁed patients referred onwards and receiving intervention as appropriate. 
Most recently, as part of the QI process, we have adopted review of STOPBANG score within the 
regular stroke multidisciplinary meetings. Further ﬁnal ﬁgures with outcome of this step shall be 
provided for the NIMAST meeting.
Conclusion: Using quality improvement methodology and securing multidisciplinary engagement can 
improve adherence to specialty guidelines.
Service development (research)
OG11.  A Song of Ice And Fire: Developing A Data Dictionary for Recording Clinical 
Concepts for Stroke In Electronic Records Using SNOMED and HL7 FHIR
Hill AM. St Helens and Knowsley Teaching Hospitals NHS Trust
Introduction: Since its introduction in 2013, the Stroke Sentinel National Audit Programme has been 
an exemplar in driving service improvement and undertaking population-level research to answer 
fundamental research questions in stroke care. The primary disadvantage of this approach is that 
collecting and maintaining the national dataset often involves expensive, manual data collection and 
validation processes. Increasing numbers of hospitals have moved to electronic records systems for 
storing of clinical records. National audit data should be fully extractable from an electronic record 
system in an automated fashion. In order to do this there must be clear deﬁnitions of the data stored 
and the form it would be expected to be found in within the record, in order to map it to the national 
dataset. This data would need to be clinically useful too, and therefore encapsulate the clinical 
concepts one would expect to ﬁnd in a stroke admission. 
43
Method: We have begun the development of a stroke data dictionary which would encapsulate all of 
the information required by the Stroke Sentinel National Audit. The SNOMED clinical coding system 
describes individual clinical concepts using unique identifying codes. These concepts can be joined 
together to form a coherent record of the patient’s admission.
The SNOMED codes are used in conjunction with the HL7 FIHR standard, which is an international 
standard used by many modern electronic record systems for storing and retrieving clinical data in 
a common database shape with standardised ‘objects’ of data. SNOMED clinical codes form the 
backbone of these objects. HL7 FIHR makes it easy to extract and exchange these objects with other 
applications. The data dictionary deﬁnes which objects one would expect to ﬁnd, and the range of 
SNOMED codes used to describe stroke concepts. This will produce an open-ended speciﬁcation, 
allowing further reﬁnement and deﬁnition of clinical terms over time.
Results: We are in the process of producing a paper for consultation describing the HL7 FIHR objects 
and associated SNOMED codes we would expect to ﬁnd within a typical stroke admission. Stroke is 
a particularly challenging area because of the highly specialised multidisciplinary working that occurs 
and specialist domain knowledge required by a range of different individuals.
Conclusion: This is an ongoing project in which I would like to engage and gain input from the wider 
stroke community. It is intended that we will have an open and shareable standard document which 
could be used to inform and guide development of electronic records, and reduce the administrative 
burden of clinical teams.
OG12.  Is it worth to keep looking for Occult Cancer in Unprovoked Venous 
Thromboembolism and Cryptogenic Stroke?
Mahmood SS, Hughes B, Gaba W, Ramadan H, Patterson C, Maguire Department of Stroke 
Medicine, Bradford Teaching Hospital, UK
Introduction: Cryptogenic stroke (CS) can be caused by paradoxical embolism (PDE) due to patent 
foramen ovale(PFO). This could be due to unprovoked venous thromboembolism (VTE) and may well 
be the earliest sign of occult cancer.
Case Report: A 59-year-old male presented with two days history of right sided visual loss and 
constipation. Past medical history included ex-smoker (20-pack-years) and a right occipital infarct 
(2009) with no cause found (CS). Systemic examination was normal except new neurological ﬁnding 
of right hemianopia. ECG showed sinus rhythm. MRI/MRA showed old right PCA infarct with acute 
left PCA infarct and normal angiogram. He was independently mobile with no symptoms/signs of 
VTE. Routine bloods were NAD. Random d-dimers were raised at 1190. He then had bilateral Venous 
Dopplers of the legs which were negative for DVT. CTPA conﬁrmed him to have asymptomatic bilateral 
PE with PFO later conﬁrmed on bubble echo. He was started on lifelong anticoagulation based on 
embolic stroke and unprovoked VTE. Thrombophilia screen, abdomino-pelvic CT and vasculitis 
screen were all negative. On follow up in clinic, PSA was found to be raised at 8.36, for which he was 
referred to urology and subsequently diagnosed with advanced prostate cancer and commenced on 
hormonal treatment.
Conclusion: Patients with cryptogenic stroke (CS) should be evaluated for presence of VTE, and if 
present should be anticoagulated. Raised d-dimers and multiple vascular territories in ischemic stroke 
suggest occult cancer. Currently there is no standardised approach to screening and it’s often up to 
clinician discretion.
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